Name | | Age | | | | | Position | Name | | Age | | | Position | Robert I. Blum | | | 5355 | | | President and Chief Executive Officer | Sharon A. BarbariDavid W. Cragg | | | 6263 | | | ExecutiveChief Human Resources and Administration Officer | Ching Jaw | | | 56 | | | Senior Vice President, Finance and Chief Financial Officer | Bonnie A. Charpentier, Ph.D. | | | 65 | | | Senior Vice President, Regulatory Affairs and Compliance | David W. Cragg | | | 61 | | | Senior Vice President, Human Resources | Fady I. Malik, M.D., Ph.D. | | | 5254 | | | Executive Vice President, Research and Development | Caryn McDowellMark A. Schlossberg, Esq. | | | 4758 | | | General Counsel and Chief Compliance Officer | Bradley P. Morgan, Ph.D. | | | 56 | | | Senior Vice President, ResearchLegal andNon-Clinical Development | Elisabeth Schnieders, Ph.D. | | | 50 | | | Senior Vice President, Business Development | Andrew A. Wolff, M.D., F.A.C.C. | | | 62 | | | Senior Vice President and Chief Medical Officer General Counsel |
Executive Skills, Experience and Background Robert I. Blum’s biography is set forth under “Board of Directors” above. Sharon A. BarbariDavid W. Cragg has served as our Executive Vice President of FinanceChief Human Resources and Chief FinancialAdministration Officer since July 2009. She served as our Senior Vice President of Finance and Chief Financial Officer from September 2004 through June 2009. From September 2002 to August 2004, she served as Chief Financial Officer and Senior Vice President of Finance and Administration of InterMune, Inc. From January 1998 to June 2002, she served at Gilead Sciences, Inc., most recently as Vice President and Chief Financial Officer. From 1996 to 1998, she served as Vice President, Strategic Planning at Foote, Cone & Belding Healthcare in San Francisco, an international advertising and marketing firm. From 1972 to 1995, she was employed by Syntex Corporation where she held various management positions in corporate finance, financial planning, marketing and commercial planning. Ms. Barbari has served on the Board of Directors of Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences, Inc.), a specialty pharmaceutical company, since March 2014. Ms. Barbari received a B.S. in Accounting from San Jose State University.
Bonnie A. Charpentier, Ph.D. joined the Company in January 2014 as our Senior Vice President of Regulatory Affairs and Compliance. Prior to joining the Company, Dr. Charpentier served as Vice President of Regulatory and Quality at CymaBay Therapeutics, Inc. (formerly Metabolex, Inc.) where she provided strategic regulatory leadership from May 2007 to January 2014. From 2001 to 2006 she served as Vice President of Regulatory and Quality at Genitope Corp. From 1995 to 2001, she held regulatory positions at Roche Global Development, a division of F.Hoffman-La Roche Ltd., including serving as Vice President and Regulatory Site Head in Palo Alto, CA. From 1991 to 1995 she held regulatory positions of increasing responsibility at Syntex Corporation. Dr. Charpentier obtained her Ph.D. in Biology from the University of Houston.
David W.February 2019. Mr. Cragg has served as our Senior Vice President, Human Resources sincefrom July 2009. He served2009 through February 2019 and as our Vice President of Human Resources from February 2005 through June 2009. From October 2000 until January 2005, Mr. Cragg managed his own human resources consulting practice. From March 2000 until its acquisition in September 2000 by Yahoo!, Inc., he was Vice President, Human Resources for eGroups Inc., an Internet email management company. Prior to October 2000, Mr. Cragg was a Principal Human Resources Consultant at Genentech, Inc. Mr. Cragg received a B.A. in Industrial Psychology from the University of California, Santa Cruz.
Ching Jaw has served as our Senior Vice President and Chief Financial Officer since June 2017. He was Chief Financial Officer of North America Pharmaceuticals and as Chair of the North America Regional Finance Council at Sanofi, a pharmaceutical company, from 2015 to 2017. From 2012 to 2015, Mr. Jaw was Chief Financial Officer for Ventana Medical Systems, a member of the Roche Group, a pharmaceutical company. Between 2001 and 2012, he held a wide variety of finance positions with Genentech Inc., now part of the Roche Group, including Chief Financial Officer of Roche in Taiwan and as Head of R&D Finance at Genentech. Mr. Jaw holds a Bachelor of Science degree in Naval Architecture from National Taiwan University, a Master of Science in Aerospace Engineering from the University of Michigan, and an M.B.A. in Finance and General Management from the University of Chicago Graduate School of Business. Fady I. Malik, M.D., Ph.D., has served as our Executive Vice President of Research and Development since November 2015. Dr. Malik served as our Senior Vice President of Research and Development from August 2014 to November 2015. Dr. Malik served as our Senior Vice President of Research and Early Development from June 2012 to August 2014. He has been with Cytokinetics since our inception in 1998, serving in a variety of roles, including Vice President, Biology from March 2008 to June 2012, all focused towards building our cardiovascular and muscle programs. Since 2000, Dr. Malik has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor and an Attending Interventional Cardiologist at the San Francisco Veterans Administration Medical Center. Dr. Malik received a B.S. from the University of California at Berkeley, a Ph.D. from the University of California at San Francisco and his M.D. from the University of California at San Francisco. Caryn G. McDowellhas served as our General Counsel and Chief Compliance Officer since May 2016. She served as our General Counsel from May 2015 to May 2016. From January 2014 to February 2015, she served as Vice President, Deputy General Counsel and Assistant Secretary of InterMune, Inc.Mark A. Schlossberg, Esq., a biopharmaceutical company, where she was primarily
EXECUTIVE OFFICERS
responsible for securities matters and commercialization. From June through December 2013, Ms. McDowell served as Associate General Counsel, Head of US Healthcare Law at Onyx Pharmaceuticals, Inc, a biopharmaceutical company (acquired by Amgen) where she lead a team of healthcare lawyers across several therapeutic areas. From 2012-2013, Ms. McDowell held the position of Executive Director, Corporate Law at Affymax, Inc., a biopharmaceutical company where she counseled the company on legal risk associated with commercialization. Prior to these positions, she served in legal roles of increasing responsibility at Genentech, and Millennium Pharmaceuticals. Prior to that, she served as Senior Counsel at the Office of the Inspector General (OIG) U.S. Department of Health and Human Services and as Assistant Attorney General Medicaid Fraud Control Unit of the Commonwealth of Massachusetts. She began her career as a litigator at Morrison Mahoney, LLP. Ms. McDowell received a J.D. from Boston University School of Law and a B.A. from the University of Michigan.
Bradley P. Morgan, Ph.D., has served as our Senior Vice President, of ResearchLegal andNon-Clinical Development General Counsel since February 2017. Dr. MorganJanuary 2019. From May 2011 to May 2018, he served as our Senior Vice President, General Counsel and Corporate Secretary of Drug Discovery and Early Development from November 2015Impax Laboratories Inc (now Amneal Pharmaceuticals, Inc.). From September 2004 to February 2016, and heMay 2011, Mr. Schlossberg served as our Vice President and Associate General Counsel of Drug Discovery and Early Development from June 2012 to November 2015. Dr. Morgan has been with Cytokinetics since 2002, serving in a variety of roles including Vice President, Chemistry, all focused towards discovery and early development of our cardiovascular and muscle programs.Amgen Inc. Prior to joining Cytokinetics, Dr. MorganAmgen, he held several scientificlegal and managementbusiness positions at Pfizer Global researchMedtronic, Inc., and development from 1993 to 2002. During that time, helegal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie
24
Alexander & Ferdon. From September 2015 until August 2017, Mr. Schlossberg served on the board of directors of Immunocellular Therapeutics Ltd., a publicly traded clinical-stage company focused on programsthe development of immune-based therapies for treatmentsthe treatment of obesity, diabetes,brain and related diseases, including nuclear receptor modulators and selectiveG-coupled protein receptor modulators. Dr. Morgan isother cancers. Mr. Schlossberg earned a memberBachelor of the American Chemical Society and of the Faculty of 1000Sciences in Pharmacology and Drug Discovery. Dr. Morgan received his Ph.D. in Chemistrybusiness administration, finance from the University of Southern California Berkeley and performed post-doctoral studies at the California Institute of Technology. Elisabeth A. Schnieders, Ph. D.has served as our Senior Vice President, Business Development since December 2016. She served as our Vice President, Business Development from November 2009 to December 2016. From January 2000 to November 2009, she held positions of increasing responsibility in business development and alliance management. From 1998 to 1999 she served as Manager, Business Development of Acacia Biosciences, a drug discovery technology company. Dr. Schnieders received a S.B. in Life Sciences from MIT and a Ph.D. in Molecular and Cell BiologyJuris Doctor degree from the University of California, Berkeley.Emory University.
Andrew A. Wolff, M.D., F.A.C.C.has served as our Senior Vice President and Chief Medical Officer since August 2014. Dr. Wolff served as our Senior Vice President of Clinical Research and Development and Chief Medical Officer from September 2004 to August 2014. From September 1994 until September 2004, Dr. Wolff held various positions of increasing responsibility at CV Therapeutics, most recently as Senior Vice President and Chief Medical Officer. From 1988 until 1994, he served in various drug development positions of increasing responsibility in both the United States and the United Kingdom for Syntex Corporation, most recently as the Executive Director of Medical Research and New Molecules Clinical Programs Leader. Since 1986, Dr. Wolff has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently an Associate Clinical Professor, and is an Attending Cardiologist in the Coronary Care Unit at the San Francisco Veterans Administration Medical Center. Dr. Wolff received a B.A. in Chemistry and Biology from the University of Dayton and an M.D. from Washington University Medical School.
25
EXECUTIVE COMPENSATIONCOMPENSATION Compensation Discussion and Analysis This Compensation Discussion and Analysis explains our compensation philosophy, policies and practices for 20162018 for the following executives,individuals, who we refer to in this Compensation Discussion and Analysis and in the following tables as our named executive officers:Named Executive Officers: Name | | | Position | Name | | Position | Robert I. Blum | | President and Chief Executive Officer | Sharon A. BarbariDavid W. Cragg | | ExecutiveChief Human Resources and Administration Officer | Ching Jaw | | Senior Vice President, Finance and Chief Financial Officer | Fady I. Malik, M.D., Ph.D. | | Executive Vice President, Research and Development | Bradley P. Morgan, Ph.D. | | Senior Vice President, Research andNon-Clinical Development | Andrew A. Wolff, M.D. | | Senior Vice President, Chief Medical Officer |
Mr. Blum is our Principal Executive SummaryOfficer, Mr. Jaw is our Principal Financial Officer. Overview of Compensation Program We design our executive compensation program to provide a competitive compensation package that focuses on corporate and individual performance and long-term results, while maximizing retention. The highlights of our 20162018 executive compensation program include: We provided merit salary increases in the range of 2% to 3.5%,3% to all members of our executive teamNamed Executive Officers in 20162018 and also granted merit salary increases to othernon-executive employees in 20162018 consistent with our past practices. We provided an annual discretionary bonus designed to reward executivesindividuals for achieving corporate goals and, except for our President and Chief Executive Officer (our “CEO”), individual goals in their functional area. Our equity program for our named executive officers has consisted ofNamed Executive Officers were granted stock options and equity awards in 2015,recognition of their performance stock units (“PSUs”). The stock options were granted in February 2015 with exercise prices equal to 100%2018. At our 2018 Annual Meeting of the fair market value on the date of grant, each vesting monthly over four years based on continued service. No PSUs were granted in 2016, but PSUs granted in August 2015 remain subject to achievement of certain performance goals. We held our second advisory stockholder vote on executive compensation at our 2014 Annual Meeting. Approximately 97%Stockholders, approximately 84% of the shares voted were cast in favor of our executive compensation. We did not hold an advisory vote on executive compensation at either of our 2015 Annual Meeting or at our 2016 Annual Meeting, as we solicit such advisory vote once every three years.for 2017. The Compensation and Talent Committee of the Board of Directors or the Committee,(the “Committee”) believes that this vote affirms our stockholders’ support for the Company’sour compensation practices. After considering the outcome of the advisory vote, the Committee made no significant changes to the executive compensation program for 2015 or 2016.2018. We willexpect to hold our next advisory vote on executive compensation at the 2017 Annual Meeting.each year.
Overview of Compensation Program
Compensation Philosophy and Objectives The Committee works to structure our executive compensation program to reward achievement of our business goals, align the executive officers’ interests with those of our stockholders and encourage our executives to build a sustainable biopharmaceutical company. The Committee seeks to ensure that we maintain our ability to attract and retain superior employees in key positions by providing our executives compensation that is competitive relative to the compensation paid to similarly situated executives in a defined group of peer companies and the broader marketplace from which we recruit and compete for talent. The Committee seeks to ensure that the total compensation paid to our executive officers is fair, reasonable, competitive and reflective of their performance and contributions toward corporate goals and objectives. To meet these objectives, we provide base salary, discretionary cash bonus, opportunities, equity awards, broad-based employee benefits with limited prerequisites, and severance benefits upon a loss of position in connection with a change in control. In determining the amount and form of these compensation elements, the Committee considers a number of factors, including: compensation levels paid to similarly situated executives by our Peer Companies (as defined below), to attract and retain executives in a competitive market for talent; corporate and individual performance, including performance in relation to our business plan, and execution of individual, team and company-wide strategic initiatives, to focus executives on achieving our business objectives; EXECUTIVE COMPENSATION
the experiences and knowledge of our executives; internal pay equity of the compensation paid to one executive officer as compared to another — that is, the compensation paid to each executive should reflect the importance of his or herthat executive’s role to the Company as compared to the roles of the other executives — to promote teamwork and contribute to retention, while recognizing that compensation opportunities should increase based on increased levels of responsibility among officers; 26
broader economic conditions, to ensure that our pay strategies account for how the larger economic environment impacts our business; and
| • | broader economic conditions, to ensure that our pay strategies account for how the larger economic environment impacts our business, such as the relatively high cost of living and competitive life science marketplace in the Bay Area; and |
the potential dilutive effect of equity awards on our stockholders. Role of the Committee The Committee is generally responsible for reviewing, modifying, approving and otherwise overseeing the compensation policies and practices applicable to all of our employees, including the administration of our equity plans and employee benefit plans. As part of its responsibilities, the Committee establishes and implements compensation decisions for our named executive officersNamed Executive Officers and evaluates the success of those decisions in supporting the Company’sour compensation philosophy for our named executive officers.Named Executive Officers. The Committee reports its decisions regarding executive compensation matters to the entire Board.Board of Directors. As part of its deliberations, in any given year, the Committee may review and consider materials such as Company financial reports, financial projections, operational data and stock performance data. The Committee also reviews information such as total compensation that may become payable to the named executive officers in various hypothetical scenarios, executive stock ownership information, analyses of historical executive compensation levels and current company-wide compensation levels and benchmarking data provided by the independent compensation consultant. The Committee also seeks input from the Committee’s independent compensation consultant and our President and Chief Executive Officer. Role of the Independent Compensation Consultant
The Committee retained Radford Surveys + Consulting, an Aon Hewitt Company or(“Radford”), the Committee’s independent compensation consultant and our CEO.
Role of the Independent Compensation Consultant The Committee retained Radford as its independent compensation consultant for compensation decisions in 2016. Pursuant to SEC rules, the2018. The Committee has assessed Radford’s independence and concluded that no conflict of interest exists that would prevent Radford from independently advising the Committee. The Committee intends to continue to assess the independence of any of our compensation advisors, consistent with applicable NASDAQNasdaq listing standards. While we pay for Radford’s services, the Compensation Committee has the authority to engage and terminate Radford’s services. Radford has no authority to make compensation decisions on behalf of the Committee or the Company. Radford may attend Committee meetings either in person or via conference call as deemed appropriate by the Committee Chair. Our management provides historical data, reviews reports for accuracy and interacts directly with Radford. The Compensation Committee, at its discretion, may also communicate and meet separately with Radford. For 2016,2018, Radford provided the following services to the Committee: reviewed and provided recommendations on the composition of our 20162018 Peer Companies; provided compensation data related to executives at our 20162018 Peer Companies based on data from SEC filings and Radford’s Life Science Survey; conducted a competitive review of the compensation of our named executive officers,Named Executive Officers, including advising on the design and structure of our equity incentive compensation program; conducted a detailed assessment of our 20162018 Peer Companies board of directors’ compensation practices and developed a summary report of findings and recommendations, including advising on the design and structure of our equity incentive compensation program; and prepared an analysis of our share usage under our equity incentive planthe 2004 EIP in comparison to our 20162018 Peer Companies based on data from SEC filings. The Company pays for the costs of Radford’s services. However, the Committee has the authority to engage and terminate Radford’s services. Although Radford makes recommendations to the Committee, it has no authority to make compensation decisions on behalf of the Committee or the Company. Radford attends Committee meetings either in person or via conference call as deemed appropriate by the Committee Chair. The Company’s management provides historical data, reviews reports for accuracy and interacts directly with Radford. The Committee, at its discretion, also communicates and meets separately with Radford.
Radford did not provide any other executive compensation services to the Companyus in 2016; however, the Company did engage2018. We separately engaged Radford to provide our management with survey data and advice regarding compensation and equity awards for our broader employee base to our management.base. The fee for these servicesthis engagement in 20162018 was less than $10,000.$20,000. The Committee approved of Radford providing these othernon-executive compensation services as it determined that these services did not constitute a conflict of interest or prevent Radford from objectively performing its work for the Committee. 27
EXECUTIVE COMPENSATION
Role of Executive Officers in Compensation Decisions For compensation decisions in 2016,2018, our President and Chief Executive OfficerCEO aided the Committee by providing recommendations regarding the compensation of all executive officersthe Named Executive Officers other than himself. Each executive officer, with the exception of our President and Chiefthose Named Executive Officer participated in an annual performance review with our President and Chief Executive OfficerCEO or their direct manager to provide input about his or her contributions to the Company’sour goals and objectives for 2016.2018. Our President and Chief Executive OfficerCEO participated in a review process, with respect to his own performance, review, with a representative from the Board of Directors and Committee member. The Committee assessed the recommendations of our President and Chief Executive OfficerCEO (and, with respect to our President and Chief Executive Officer,CEO, the recommendations of the Board of Directors’ representative) in the context of each executive officer’sNamed Executive Officer’s performance. No executive officerNamed Executive Officer participated directly in the Committee’s final determinations regarding the amount of any component of his or her own 2016 compensation package.2018 compensation. Our Human Resources, Finance and Legal departments work with our President and Chief Executive OfficerCEO to design and develop compensation programs for our named executive officers,Named Executive Officers, to recommend changes to existing compensation programs, to establish corporate and individual performance goals, to prepare peer data comparisons and other Committee briefing materials and ultimately to implement the Committee’s decisions. Our Senior Vice President, Human Resources and our President and Chief Executive OfficerCEO meet separately with Radford to convey information on proposals that management may make to the Committee, as well as to assist Radford in collecting information about the Companyus to perform its duties for the Committee. Benchmarking The Committee believes it is important when making its compensation-related decisions to be informed as to current compensation practices of comparable publicly held companies in the life sciences industry. To obtain independent and expert advice on appropriate compensation, theThe Committee engagesengaged Radford to analyze the executive compensation practices of a number of comparable publicly held companies in the life sciences industry or our Peer Companies.(the “Peer Companies). The Committee, in consultation with Radford, reviews and adjusts the list of Peer Companies annually to ensure that the list provides a current and useful comparison of companies for use as a means of comparing our executive compensation levels relative to the market. The Committee approved the following Peer Companies for use in making compensation decisions in 2016:
| | | | | • Acceleron Pharma
| | • Five Prime Therapeutics, Inc.
| | • Rigel Pharmaceuticals, Inc. | • Amicus Therapeutics, Inc.
| | • Geron Corporation
| | • Sangamo Biosciences, Inc. | • Anthera Pharmaceuticals, Inc.
| | • Infinity Pharmaceuticals, Inc.
| | • Synta Pharmaceuticals, Inc. | • ArQule, Inc.
| | • Omeros Corporation
| | • Theravance Biopharma | • Array Biopharma, Inc.
| | • OncoMed Pharmaceuticals, Inc.
| | • Threshold Pharmaceuticals, Inc. | • ChemoCentryx, Inc.
| | • Peregrine Pharmaceuticals, Inc.
| | • XenoPort, Inc. | • Concert Pharmaceuticals, Inc.
| | • Regulus Therapeutics
| | • Xoma Corporation |
Companies are evaluated and adjusted as appropriate for inclusion in these analyses based on business characteristics similar to ours. Potential companies are selected based on criteria that include business model, stage of development, market capitalization, year of initial public offering, employee headcount, research and development expenditures, cash reserves and revenue. In late 2017, The Committee selectedapproved the 2016following Peer Companies for use in November 2015. making compensation decisions in 2018: • Acceleron Pharma | | • Esperion Therapeutics | • Achaogen | | • Five Prime Therapeutics | • Akebia Therapeutics | | • Geron Corporation | • Ardelyx | | • Karyopharm Therapeutics | • Atara Biotherapeutics | | • Myokardia | • BioCryst Pharmaceuticals | | • Omeros Corporation | • Calithera Biosciences | | • Rigel Pharmaceuticals, Inc. | • ChemoCentryx | | • Sangamo Biosciences, Inc. | • Concert Pharmaceuticals | | • Tetraphase Pharmaceuticals | | | |
At the time of the determination, these companies each had a market capitalization between $123$116 million and $936 million,$1.7 billion, had an employee head count between 201, and 287,195, and were generally at a comparable stage to us in the development of their lead drug candidate. The Committee determined that the foregoing selection criteria were appropriate for selecting the 2016 Peer Companies for 2018 because at such time, Cytokinetics waswe were a late-stage biopharmaceutical company with a market capitalization of approximately $274$410 million and 92127 employees. After the 2016 Peer Companies were selected, Radford prepared an extensive analysis of the compensation practices of the Peer Companies as reported in their proxy statements, and offered additional analysis based on the compensation practices of a broadercomparable group of life science companies (a subset of what is included in the broader Radford Life Science Survey).
The Committee reviewed the cash and equity components from these benchmarking analysisanalyses in setting a total compensation package for each executive officer while alsoas well as reviewing each executive officer’s past and anticipated contributions to the Company, current compensation package, compensation market trends for competitive positions, retention EXECUTIVE COMPENSATION
risks and overall Company performance. While benchmarking information alone is not sufficient for setting compensation, theThe Committee believes that considering this benchmark information is anto be important aspect of diligence in 28
compensation-related decisions. Other factors, such as economic conditions and internal pay equity and individual negotiations may play an important role with respect to the compensation offered to an executive in any given year. In general and in line with the Company’s general compensation philosophy, when considering the Peer Company data, theThe Committee aims to provide target total cash and long-term equity compensation at or around the median of the compensation paid to similarly situated executives employed by the Peer Companies for target level performance, with compensation above this level possible for exceptional performance. To achieve this positioning for target levels of compensation, the Committee generally sets the various compensation elements as follows:
base salaries between the 50th and 75th percentile for comparable positions; | • | | base salaries between the 50th and 75th percentile for comparable positions;
|
target cash bonus compensation at a level such that, when combined with base salary, the target total cash compensation is at or around the median for comparable positions; and target long-term equity compensation at a level such that, when combined with target total cash compensation, target total cash and equity compensation is at or around the median for comparable positions. When reviewing base salary the Committee takes into consideration the high cost of living and competitive life science marketplace in the Bay Area. In order to attract and retain key talent they believe it is appropriate to have a more meaningful level of fixed compensation in the form of base salary (between the 50th and 75th percentiles of the Peer Companies) to achieve this objective.
Compensation Components Base Salary. We provide base salary as athe fixed source of compensation for our executive officers for the services they provide to us during the year and to balance the impact of having the bulk of the remainder of their compensation “at risk” in the form of discretionary annual cash bonuses and equity-based incentive compensation. The Committee recognizes the importance of base salaries as an element of compensation that helps to attract and retain talented executives. Annual Bonus. We believe that base salaries should be consistent with the salaries provided by our Peer Companies. The Committee targets base salary between the 50th and 75th percentiles of the Peer Companies. The Committee believes this positioning is necessary to attract and retain executives in the San Francisco Bay Area where the cost of living is higher than much of the country, and to enable us to recruit executive talent from companies that are at a more mature stage of development and therefore may have greater resources to provide higher base compensation, higher total compensation, greater job security and increased employee benefits. The Committee generally reviews base salaries annually and adjusts base salaries if necessary to remain at the desired benchmark level as compared to the Peer Company data. The Committee also takes into account each executive’s individual responsibilities, performance during the prior fiscal year and experience in deciding whether the benchmark percentile is the correct positioning for that executive that year. Additionally, in determining base salary increases, the Committee considers the Company’s overall budget for merit salary increases for the year, and whether an executive officer was promoted or his or her responsibilities were or are expected to be modified during the year. The Company’s 2016 budget for merit salary increases for all employees was an aggregate increase of 3% over the 2015 salary base salaries. There was no separate merit salary increase budget for our named executive officers.
The 2016 base salaries and the percentage increase of the prior year’s base salary for each of the named executive officers were as follows:
| | | | | | | | | Named Executive Officer | | 2016 Base Salary | | | % increase from 2015 | | Robert I. Blum | | | $595,000 | | | | 3.5% | | Sharon A. Barbari | | | $412,798 | | | | 2.5% | | Fady Malik, M.D., Ph.D. | | | $449,694 | | | | 2.5% | | Bradley P. Morgan, Ph.D. | | | $332,227 | | | | 3.0% | | Andrew A. Wolff, M.D. | | | $395,760 | | | | 2.0% | |
Annual Bonus. We structurestructured our annual cash bonuses to provide incentives for our executive officersNamed Executive Officers to achieve our annual corporate and individual performance objectives.
Target Bonuses.Each named executive officer’sNamed Executive Officer’s annual target bonus is expressed as a percentage of his or her base salary and is set at a level that, upon 100% achievement of the Company’sour corporate goals and the named executive officer’s
EXECUTIVE COMPENSATION
Named Executive Officer’s individual performance goals, falls at the median level for a similar executive position as compared to the Peer Company data. In determining the split of the target bonus as between corporate and individual performance, the Committee believes that the more senior a named executive officer’sNamed Executive Officer’s position and operational responsibilities, within the Company, the greater the percentage of his or her bonus that should be weighted to our corporate rather than individual achievement. For example, our President and Chief Executive Officer’s bonus is based entirely on corporate achievement and not on individual achievement. Target bonus levels for 2016 performance for each of the named executive officers, expressed as a percentage of base salary, and the relative weightings of individual goals and corporate goals, were as follows:
| | | | | | | | | | | | | Named Executive Officer | | Target Bonus % of Salary | | | Individual Goal Weighting | | | Corporate Goal Weighting | | Robert I. Blum | | | 60% | | | | 0% | | | | 100% | | Sharon A. Barbari | | | 40% | | | | 25% | | | | 75% | | Fady Malik, M.D., Ph.D. | | | 40% | | | | 25% | | | | 75% | | Bradley P. Morgan, Ph.D. | | | 35% | | | | 25% | | | | 75% | | Andrew A. Wolff, M.D. | | | 35% | | | | 25% | | | | 75% | |
The 2016 target bonus levels were at the median level for similar executive positions as compared to the 2016 Peer Company data.
In the first quarter of each year, the Committee reviews and approves corporate goals presented by senior management. The Committee does weighweighs the goals but does not establish a specific performance formula. Rather, the Committee determines actual bonuses in a subjective fashion at the end of the year, taking into accountconsidering the original goals and any other factors the Committee determines are material, in its discretion. The minimum bonus amount is zero, and the maximum is 120% of the target bonus amount. If the Committee determines that bonuses should not be awarded for corporate achievement for any reason, bonuses will not be paid even if the individual achievements were met. We believe this fully discretionary bonus structure allows the Committee to be responsive to the uncertainties and lack of predictability associated with being a biotechnology company dedicated to the discovery, development and commercialization offirst-in-class therapeutics with novel mechanisms of action. The individual and corporate goals for 2016 are described in more detail in the section titled “Corporate and Individual Achievement Assessment.” Equity Awards. The Committee believes that providing a material portion of our executive officers’ total compensation in equity awards aligns the interests of our executive officers with our stockholders, by linking the value of compensation to the value of our Common Stock. In determining the form and size of equity awards, the Committee considers information provided by Radford as to whether the complete compensation packages provided to each named executive officer,Named Executive Officer, including prior equity awards, are sufficient to retain, motivate and adequately reward the executive for his or her contributions. In addition, in determining the size of equity awards, the Committee considers the anticipated value of the named executive officer’sNamed Executive Officer’s contributions going forward. We make new-hire and subsequent equity awards on pre-determined dates as follows: Before an offer is made, the Committee approves the terms of new-hire equity awards above the senior director level. The Committee has authorized the CEO to approve new hire equity awards, within pre-approved guidelines, at or below the senior director level. We generally grant subsequent equity awards to all eligible employees during the first quarter of each fiscal year. 29
We do not purposely accelerate or delay the public release of material information in consideration of a pending equity awards to allow the grantee to benefit from a more favorable stock price. We encourage our executives to hold a significant equity interest in the Company, but we have not set specific ownership guidelines. We have a policy that prohibits our executives, directors and other members of management from engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative transactions with respect to our stock. Stock Options.We grant stock options to our named executive officersNamed Executive Officers when they join us and annually, on a discretionary basis, as part of our performance review and rewards process. All options have an exercise price equal to the fair market value of our Common Stock on the date of grant, and generally vest monthly based on continued service over a four-year period (with aone-year cliff for new hire grants). As a result of our option grant structure, the optionsOptions provide a return to the executive officer only if the executive officer remains a service provider to the Company,us, and then only if the market price of our Common Stock appreciates relative to the option exercise price over the period in which the option vests and beyond. Restricted Stock Awards (RSUs): In 2018, after reviewing practices of our peers and in conjunction with the recommendations of our compensation consultants, we granted a blend of stock options and RSUs to our Named Executive Officers. We believe this blended approach will enable us to retain a competitive position and enhances the retention of key talent. In determining the size of stock option grantsequity awards to executive officersNamed Executive Officers in a given year, the Committee may consider: for each executive officer,Named Executive Officer, the value of equity awards granted to executives in similar positions at our Peer Companies, targeting long-term equity compensation at a level such that, when combined with target total cash compensation, the officer’s target total compensation opportunity is at or around the median for comparable positions; the equity budget for a given year for all of our employees, and the percentage of that budget allocated to be used for awards to our named executive officers;Named Executive Officers; the retention and motivation value of equity awards that have been previously granted to each executive officer;Named Executive Officer; each executive officer’sNamed Executive Officer’s total potential ownership as a percentage of our total outstanding shares; and internal pay equity among our named executive officers,Named Executive Officers, to reflect the importance of each officer’sNamed Executive Officer’s responsibilities for the Company’sto our success as compared to our other Named Executive Officers. Broad-based employee benefits with limited prerequisites. Our Named Executive Officers are eligible to participate in our employee benefit plans, including medical, dental, life insurance, employee stock purchase and 401(k) plans. These benefits are available on the other executive officerssame terms and our President and Chief Executive Officer. EXECUTIVE COMPENSATION
The number of shares underlying stock options grantedconditions as to our named executive officers in February 2016 was as follows:
| | | | | Named Executive Officer | | Option Shares | | Robert I. Blum | | | 275,000 | | Sharon A. Barbari | | | 90,000 | | Fady Malik, M.D., Ph.D. | | | 100,000 | | Bradley P. Morgan, Ph.D. | | | 50,000 | | Andrew A. Wolff, M.D. | | | 40,000 | |
Except for the PSU’s granted in 2015, no other form of equity awards were grantedemployees. Our Named Executive Officers do not receive any perquisites other than those provided to named executive officers in 2016, 2015 or 2014.
Corporate and Individual Achievement Assessment Impacting Compensation Components
Corporate Achievement. Before the start of each calendar year, management prepares a set of corporate goals covering our expected operating and financial performance for the fiscal year. Our corporate goals are focused on corporate metrics and objectives that are intended to provide both near- and long-term stockholder value. The Committee then reviews and approves these corporate goals.
For 2016, the Committee approved corporate goals related to:
completing patient enrollment inVITALITY-ALS, the Phase 3 clinical trial of tirasemtiv, in patients with ALS; initiatingVIGOR-ALS, the open-label clinical for patients who have completedVITALITY-ALS; developing a New Drug Application/Marketing Authorization Application and commercial readiness plan for tirasemtiv;
collaborating with Regulatory Affairs and Amgen to complete End of Phase 2 regulatory interactions in North America and Europe intended to result in a final agreed Phase 3 protocol and Special Protocol Assessment, for omecamtiv mecarbil, a novel investigational cardiac myosin activator and guide collaboration to start pivotal Phase 3 outcomes trial of omecamtiv mecarbil in 2016;
completing patient enrollment in the first cohort of CY 5021, the Phase 2 clinical trial ofCK-2127107 in patients with Spinal Muscular Atrophy;
supplying material of our drug candidates for use in our skeletal muscle contractility development programs;
advancing our research programs to lead optimization and candidate selection, and conducting a early research program selection process;
raising capital and corporate partnering for our programs, including receipt of funds; and
managing the budget to close the fiscal year with sufficient cash to cover projected expenditures for the following eighteen months.
At the end of each year, the Committee determines the overall level of corporate achievement, including assessing our performance relative to these goals. The Committee does not use a rigid formula in determining the Company’s level of achievement, but instead considers:
the degree of success achieved for each corporate goal, comparing actual results against thepre-determined deliverables associated with each objective;
the difficulty of the goal;
whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the desired results;
other factors that may have made the stated goals more or less important to our success; and
other accomplishments by us during the year or other factors which, although not included as part of the formal goals, are nonetheless deemed important to our near- and long-term success.
The Committee does assign weightings to the goals by functional area, but uses its discretion and judgment to determine a percentage that it believes fairly represents our achievement level for the year.
Individual Achievement.Individual goals for each named executive officer are derived from the corporate goals that relate to his or her functional area, except for our President and Chief Executive Officer, who has no individual goals apart from the corporate goals. Our President and Chief Executive Officer establishes the individual goals with each other named executive officer described below based on the relevant corporate goals and key functional area priorities for the year.
EXECUTIVE COMPENSATION
Ms. Barbari’s 2016 goals related to supporting partnering activities and providing financial analyses as needed for deal structures, recruiting staff to ensure continuity in workflow and reduce dependency on outside consultants, raising capital, managing the implementation of upgrades to our financial systems, managing spending within the Board-approved net operating budget and developing contingency plans to address future cash requirements, ensuring compliance with internal controls as required by COSO andAS-5, managing the development of Information Technology Commercial Readiness plans and meeting SEC reporting compliance requirements and supporting the presentation of key clinical data with appropriate investor events.
Dr. Malik’s 2016 goals related to advancing research programs to candidate selection andhit-to-lead stages, collaborating with Amgen on the development program for omecamtiv mecarbil and thefollow-on research program directed to next-generation compounds in our cardiac muscle contractility program, providing high quality, clinical trial supplies, directing the conduct of ourVITALITY-ALS,VIGOR-ALS andCK-2127107 clinical trials.
Dr. Morgan’s 2016 goals related to collaborating with Commercial Planning to develop a Strategic Plan and Budget for the commercial supply of tirasemtiv to support a potential launch inmid-2018, guiding our early research programs process and overseeing Medical Chemistry, Analytical Chemistry, Automation & Technology and theNon-Clinical Development groups. His goals also included leading the efforts of candidate selection and to advance our Research programs and continued support of both our collaborations and their drug development programs.
Dr. Wolff’s 2016 goals related to providing clinical guidance and support to theVITALITY-ALS Phase 3 clinical study. Assisting the Regulatory team with strategy, document review and drafting and participating in Regulatory Agency meetings. Overseeing external collaborations with Amgen on Phase 3 study protocol for omecamtiv mecarbil. Asco-chair of the Astellas Joint Development Committee continue to define the development ofCK-2127107all employees.
At the end of each year, the Committee, with input from our President and Chief Executive Officer, determines the overall level of individual achievement for each named executive officer, which includes, but is not limited to, an assessment of the executive’s performance relative to these goals. The Committee does not use a rigid formula in determining each executive officer’s level of achievement, but considers:
the degree of success achieved against the specific deliverables associated with each objective;
the difficulty of the goal;
whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the desired results;
the overall performance of the functional areas for which the executive officer has responsibility;
the manner in which the executive officer contributes to the overall success of the Company, including areas outside of his or her responsibility;
the overall management of the executive officer’s staff;
other factors that may have made the stated goals more or less important to our success; and
other accomplishments by the executive officer during the year which, although not included as part of the formal goals, are nonetheless deemed important to our near- and long-term success.
The Committee does not assign weights in these assessments, but uses its discretion and judgment to determine, based on recommendations by the President and Chief Executive Officer, a percentage that it believes fairly represents the named executive officer’s individual achievement level for the year.
2016 Executive Compensation Decisions
Corporate Achievement Level
In February 2017, the Committee determined that the Company had an overall corporate achievement level of 95% for 2016. This determination was based on progress in the advancement of the Company’s skeletal and cardiac muscle R&D programs, the achievement of research program milestones, and the expansion of a collaboration agreement. The Committee considers these achievements alongside progress toward achieving business development goals, and other financing objectives and certain research goals.
Individual Achievement Levels
Mr. Blum’s individual achievement level is based solely on the corporate achievement level, which for 2016 was 95%, as discussed above. In February 2017, the Committee determined that the other named executive officers had individual achievement levels for 2016, based on their individual goals for 2016 and achievements against them described above, as follows: Ms. Barbari — 95%; Dr. Malik — 95%; Mr. Morgan — 95%; and Dr. Wolff — 87%.
EXECUTIVE COMPENSATION
Robert I. Blum.
| • | | Salary. The Committee granted a merit salary increase to Mr. Blum in 2016 of 3.5%. Accordingly, Mr. Blum’s base salary for 2016 was $595,000.
|
| • | | Bonus. In February 2017, the Committee awarded Mr. Blum a bonus for 2016 performance of $350,000, or 59% of his 2016 base salary. This was based on a target bonus of 60% of his base salary, multiplied by the corporate achievement level of 95%, however the Board did exercise some discretion in determining the final bonus amount.
|
| • | | Equity.In February 2016, the Committee awarded Mr. Blum stock options to purchase 275,000 shares of common stock in consideration of his performance as President and Chief Executive Officer in 2015. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies, which resulted in targeted cash and equity compensation at or around the median.
|
Sharon A. Barbari.
| • | | Salary. The Committee granted a merit salary increase to Ms. Barbari in 2016 of 2.5%. Accordingly, Ms. Barbari’s base salary for 2016 was $412,798.
|
| • | | Bonus. In February 2017, the Committee awarded Ms. Barbari a bonus for her 2016 performance of $156,863, or 38% of her 2016 base salary. This was based on a target bonus of 40% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for her individual achievement level of 95% and 75% for the corporate achievement level of 95%).
|
| • | | Equity. In February 2016, the Committee awarded Ms. Barbari stock options to purchase 90,000 shares of common stock. In determining the size of the award, the Committee considered her contribution with managing financial resources in 2015 which resulted in cash reserves in excess of those required to cover capital expenditure in the months following. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median.
|
Fady Malik.
| • | | Salary. The Committee granted a merit salary increase to Dr. Malik in 2016 of 2.5%. Accordingly, Dr. Malik’s base salary for 2016 was $449,694.
|
| • | | Bonus. In February 2017, the Committee awarded Dr. Malik a bonus for his 2016 performance of $170,884 or 38% of his 2016 base salary. This was based on a target bonus of 40% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for his individual achievement level of 95% and 75% for the corporate achievement level of 95%).
|
| • | | Equity.In February 2016, the Committee awarded Dr. Malik stock options to purchase 100,000 shares of common stock. In determining the size of the award, the Committee considered his contributions in research, preclinical and nonclinical development areas in 2016. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median.
|
Bradley Morgan.
| • | | Salary. The Committee granted a merit salary increase to Mr. Morgan in 2016 of 3%. Accordingly, Mr. Morgan’s base salary for 2016 was $332,227.
|
| • | | Bonus.In February 2017, the Committee awarded Mr. Morgan a bonus for his 2016 performance of $110,465 or 33% of his 2016 base salary. This was based on a target bonus of 35% of base salary, multiplied by an overall achievement level of 95% (based on a weighting of 25% for his individual achievement level of 95% and 75% for the corporate achievement level of 95%).
|
| • | | Equity.In February 2016, the Committee awarded Mr. Morgan stock options to purchase 50,000 shares of common stock. In determining the size of the award, the Committee considered his contributions in 2016 in meeting the goals related to drug discovery and early development. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median.
|
Andrew Wolff.
| • | | Salary. The Committee granted a merit salary increase to Dr. Wolff in 2016 of 2%. Accordingly, Dr. Wolff’s base salary for 2016 was $395,760.
|
EXECUTIVE COMPENSATION
| • | | Bonus.In February 2017, the Committee awarded Dr. Wolff a bonus for his 2016 performance of $100,000 or 25% of his 2016 base salary. This was based on management discretion.
|
| • | | Equity.In February 2016, the Committee awarded Dr. Wolff stock options to purchase 40,000 shares of common stock. In determining the size of the award, the Committee considered his contributions in 2016 in meeting the goals related to medical affairs. This award was within the targeted equity award range based on an analysis of data from our 2016 Peer Companies which resulted in targeted cash and equity compensation at or around the median.
|
2017 Compensation Decisions
In February 2017, the Committee made the following decisions with respect to the compensation of the named executive officers.
| | | | | | | | | | | | | | | | | Named Executive Officer | | 2017 Base Salary | | | Option Shares | | | RSU’s | | | Target Bonus as a % of Base Salary | | Robert I. Blum | | | $615,000 | | | | 205,000 | | | | 60,000 | | | | 60% | | Sharon A. Barbari | | | $425,182 | | | | — | | | | — | | | | 40% | | Fady I. Malik | | | $463,185 | | | | 50,000 | | | | 30,000 | | | | 40% | | Bradley P. Morgan, Ph.D. | | | $342,194 | | | | 20,000 | | | | 20,000 | | | | 35% | | Andrew A. Wolff, M.D. | | | $403,675 | | | | 15,000 | | | | 15,000 | | | | 35% | |
Severance Benefits and Employment Agreements Agreements. We have entered into Executive Employment Agreements with each of our named executive officers. These agreementsNamed Executive Officers that provide for salary and benefit continuation, bonus payments and accelerated vesting of equity awards upon the termination of their employment either by us without cause, or by the executive for good reason following a loss of position in connection with a change of control of the Company. The terms of these agreements are described in more detail in the section below entitled “Potential Payments Upon Change of Control.” In addition, our equity plan provides that all employee equity awards will be subject to full acceleration if they are not assumed or replaced with comparable awards by the acquirer. The Committee believes these severance and change of control benefitsagreements are an essential element of our executive compensation packageprogram and assist itassists the Committee in recruiting and retaining talented executive officers.executives. The Committee also believes these benefits serve to minimize the distractions to the executive, reduce the risk that the executive will depart the Company before an acquisition is consummated, and allow the executive to focus on continuing normal business operations and the success of a potential business combination, rather than worrying about how business decisions that may be in our best interests and the best interest of the Company and itsour stockholders will impact his or her own financial security. That is, these change of control arrangements help ensure stability among our executive officer ranks and will enable our executives to maintain a balanced perspective in making overall business decisions during periods of uncertainty. Further, these agreements are in line with customary practices at an executive officer level at the Peer Companies. Other30
Corporate and Individual Achievement Assessment Impacting Compensation Components Corporate Achievement. Before the start of each calendar year, management prepares a set of corporate goals covering our expected operating and financial performance for the fiscal year. Our executive officerscorporate goals are eligiblefocused on corporate metrics and objectives that are intended to participateprovide both near- and long-term stockholder value. The Committee then reviews and approves these corporate goals. For 2018, the Committee approved corporate goals included: Advancement of development candidates from research into IND-enabling studies, Guiding collaboration with Amgen to enable an additional Phase 3 trial for omecamtiv mecarbil, Conduct of our Phase 2 clinical trial of reldesemtiv in patients with Spinal Muscle Atrophy, Conduct of FORTITUDE-ALS, our employee benefit plans,Phase 2 clinical trial of reldesemtiv in patients with ALS, Corporate development activities, and Achieving financial management objectives. At the end of each year, the Committee determines the overall level of corporate achievement, including medical, dental, life insurance, employee stock purchase and 401(k) plans. These benefits are availableassessing our performance relative to these goals. The Committee does not use a rigid formula in determining the Company’s level of achievement, but instead considers: the degree of success achieved for each corporate goal, comparing actual results against the pre-determined deliverables associated with each objective; the difficulty of the goal; whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the desired results; other factors that may have made the stated goals more or less important to our executivessuccess; and other accomplishments by us during the year or other factors that, although not included as part of the formal goals, are nonetheless deemed important to our near- and long-term success. Individual Goals. Individual goals for each Named Executive Officer are derived from the corporate goals that relate to his or her functional area, except for our CEO, who has no individual goals apart from the corporate goals. Our CEO establishes the individual goals for 2018 with each other Named Executive Officer described below based on the same termsrelevant corporate goals and conditionskey functional area priorities for the year. Mr. Cragg’s goals included human resources and corporate development objectives. Mr. Jaw’s goals included corporate development objectives and achieving financial management objectives. Dr. Malik’s goals included advancement of research and development candidates and clinical trial milestone achievements. Target bonus levels for 2018 performance for each of the Named Executive Officers expressed as our other employees. Our executive officers do not receive any perquisites other than those provided to all employees. Equity Compensation Policies
Our policy is to makenew-hirea percentage of base salary, and annual equity grants onpre-determined datesthe relative weightings of individual goals and corporate goals, were as follows:
Named Executive Officer | | Target Bonus % of Salary | | | Individual Goal Weighting | | | Corporate Goal Weighting | | Robert I. Blum | | 60% | | | 0% | | | 100% | | David W. Cragg | | 35% | | | 25% | | | 75% | | Ching Jaw | | 40% | | | 25% | | | 75% | | Fady I. Malik, M.D., Ph.D. | | 40% | | | 25% | | | 75% | |
The 2018 target bonus levels were at the median level for similar executive positions as compared to the Peer Company data for 2018. 2018 Compensation Decisions In February 2018, based on progress in the advancement of our skeletal and cardiac muscle programs, the achievement of research program milestones, the expansion of a collaboration agreement, progress toward business development goals, other financing objectives and certain research goals, the Committee determined that the Company 31
had an overall corporate achievement level of 80% for 2017. The Committee also determined the overall level of individual achievement for each Named Executive Officer, which includes, but is not limited to, an assessment of the individual’s performance relative to these goals. The Committeepre-approves new hire stock option grants above does not use a rigid formula in determining each Named Executive Officer’s level of achievement, but considered: the senior director level, including our executive officers, before an offer is made. The Committee has delegated to Robert I. Blum, as President and Chief Executive Officer,degree of success achieved against the authorization to approve new hire stock option grants, withinpre-approved new hire grant guidelines, for new hires at or below specific deliverables associated with each objective; the senior director level before an offer is made. New hire stock options are granted on the last daydifficulty of the monthgoal; whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the desired results; the overall performance of the functional areas for which the individual has responsibility; the manner in which the employee is hired.individual contributes to our overall success, including areas outside of his or her responsibility; We make annual equity grants, on a discretionary basis,the overall management of the individual’s staff;
other factors that may have made the stated goals more or less important to our success; and other accomplishments by the executive officer during the year that, although not included as part of the formal goals, are nonetheless deemed important to our performance reviewnear- and reward process. long-term success. The Committee makes annual grantsdoes not assign weights in these assessments, but uses its discretion and judgment to employees atdetermine a Committee meeting held duringpercentage that it believes fairly represents the first quarter of each fiscalindividual’s achievement level for the year. EXECUTIVE COMPENSATION
The exercise price of the stock optionsMr. Blum’s individual achievement level is not less than the closing price of our Common Stockbased solely on the NASDAQ Capital Market oncorporate achievement level. In February 2018, the grant dateCommittee:
| (i) | determined that the other Named Executive Officers had individual achievement levels for 2017 as follows: Mr. Cragg – 90%, Mr. Jaw – 90% and Dr. Malik — 85%; and |
| (ii) | increased base salaries, granted bonus amounts and granted equity awards for Named Executive Officers. |
The Committee exercised some discretion in determining changes to compensation. The following summarizes changes to individual compensation for our Named Executive Officers in 2018, with base salary changes effective March 1, 2018: Robert I. Blum Salary. Increased base salary from $615,000 to $633,450. Bonus. Awarded a bonus of $295,200 for his performance in 2017. Equity. Granted options to purchase 200,000 shares of common stock and 100,000 RSUs. David W. Cragg Salary. Increased base salary from $317,448 to $336,495. Bonus. Awarded a bonus of $91,663 for his performance in 2017. Equity. Granted options to purchase 40,000 shares of common stock and 30,000 RSUs. Ching Jaw Salary. Increased base salary from $410,000 to $416,150. Bonus. Awarded a bonus of $67,650 for his performance in 2017. Equity. Granted options to purchase 40,000 shares of common stock and 20,000 RSUs. Fady Malik Salary. Increased base salary from $463,185 to $477,081. Bonus. Awarded a bonus of $150,535 for his performance in 2017. Equity. Granted options to purchase 75,000 shares of common stock and 40,000 RSUs. 32
2019 Compensation Decisions In February and March 2019, the option. Our policy is notCommittee, after exercising its discretion, voted to purposely accelerate or delay the public release of material information in considerationapprove salary increases, payment of a pendingcash bonus and equity grant to allowawards for the grantee to benefit from a more favorable stock price. We encourage our executive officers to hold a significant equity interest in the Company, but we have not set specific ownership guidelines. We have a policy that prohibits our executive officers, directors and other members of management from engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative transactionsCompany’s Named Executive Officers with respect to our stock.base salary changes effective March 1, 2019.
Named Executive Officer | | 2019 Base Salary | | | Cash Bonus for 2018 | | | Option Grants | | | RSU Grants | | | Target Bonus % of Salary | | Robert I. Blum | | $ | 660,000 | | | $ | 250,000 | | | | 240,000 | | | | 120,000 | | | 60% | | David W. Cragg | | $ | 383,604 | | | $ | 95,641 | | | | 50,000 | | | | 30,000 | | | 40% | | Ching Jaw | | $ | 432,796 | | | $ | 110,000 | | | | 50,000 | | | | 30,000 | | | 40% | | Fady I. Malik, M.D., Ph.D. | | $ | 496,164 | | | $ | 150,281 | | | | 80,000 | | | | 50,000 | | | 40% | |
Tax Deductibility of Executive Compensation Section 162(m) of the Code limits the amount that a public companyPublicly-held companies may not deduct from federal income taxes for remunerationcompensation paid to the chief executive officer and the three other most highly paidcertain executive officers other thanto the chief financial officer, to $1.0extent such compensation exceeds $1 million per executive per year, unless certain requirements are met. Section 162(m) provides an exceptionofficer in any year. The exemption from this deduction limitationlimit for “performance-based compensation” was repealed for taxable years beginning after December 31, 2017, such that compensation paid to our certain formsemployees in excess of “performance-based$1 million will not be deductible unless the compensation” qualifies for transition relief applicable to certain arrangements in place as of November 2, 2017.
The Committee will continue to monitor potential tax deduction limitations to its ongoing compensation arrangements. Because of ambiguities and uncertainties as to the application and interpretation of tax law and the regulations issued thereunder, including the gain recognized by executive officers uponuncertain scope of the exercisetransition relief under the legislation repealing the “performance-based compensation” exemption from the deduction limit, no assurance can be given that any compensation that may have been (or if granted under a binding written contract in place as of qualifying compensatory stock options.November 2, 2017 may be) intended to satisfy the requirements for exemption from these limitations, in fact will be exempt. In determining the form and amount of compensation for our Named Executive Officers, the Committee may continue to consider all elements of the cost of such compensation, including the potential impact of deduction limitations. While the Committee is mindfulconsiders the deductibility of the benefit to us of the full deductibility ofawards as one factor in determining executive compensation, the Committee believesmay also look at other factors in making its decisions, and retains the flexibility to award compensation that it should notdetermines to be constrained byconsistent with the requirementsgoals of Section 162(m) where those requirements would impair flexibility in compensating our executive officers in a manner that can best promote our corporate objectives. Accordingly, although our grants of stock options to our executive officers will be considered “performance-based compensation” under Section 162(m), their annual cash bonuses,compensation program even if any, will not. We intend to continue to compensate our executive officers in a manner consistent with what we believethe awards are the best interests of the Company and our stockholders.not deductible by us for tax purposes. Accounting Considerations In determining the size and type of equity awards, the Committee considers the potential impact of the accounting guidance for stock-based compensation. However, weWe do not set a specific budget for equity compensation based on the accounting cost. Compensation Recovery Policy One of the objectives of our compensation program for our named executive officersNamed Executive Officers is to make a substantial portion of compensation paid to our executive officers dependent on the Company’sour overall financial performance. In order to ensure that our named executive officersNamed Executive Officers take full account of risks to the Companyus and itsour stockholders in their decision-making, and to reduce such risks wherever practicable, our Board adopted a clawback policy and delegated authority to its Compensationthe Committee to administer it. Our clawbacka policy that allows the Companyus to seek repayment of incentive compensation that was erroneously paid. Thepaid, commonly referred to as a Clawback Policy. This policy provides that if the Board, or Compensationthe Committee as applicable, determines that there has been a material misstatement of publicly issued financial results from those previously issued to the public [duedue to a knowing violation of SEC rules and regulations of the Securities and Exchange Commission or Company policy,our policies, or the willful commission of an act of fraud, dishonesty, gross recklessness or gross negligence],negligence, our Board or Compensation Committee will review all incentive compensation made to our [executive] officersNamed Executive Officers during the [three] yearthree-year period prior to the restatement on the basis of having met or exceeded specific performance targets. If such payments would have been lower had they been calculated based on such restated results, our Board or Compensation Committeewe will (to the extent permitted by governing law) seek to recoup the payments in excess of the amount that would have been paid based on the restated results.
In addition, as a public company subject to Section 304 of the Sarbanes-Oxley Act of 2002, if we are required as a result of misconduct to restate our financial results due to the material noncompliance with any financial reporting requirements under the federal securities laws, our President and Chief Executive Officer and Executive Vice President, Finance and Chief Financial Officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they received. In addition, we will comply with the requirements of the Dodd-Frank Wall Street Reform 33
Compensation and Consumer Protection Act and will adopt a compensation recovery policy once the SEC adopts final regulations on the subject. Talent Committee ReportEXECUTIVE COMPENSATION
Our Compensation and Talent Committee Report The Compensation and Talent Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of RegulationS-K with management and, based on such review and discussions, the Compensation and Talent Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.
MEMBERS OF THE COMPENSATION AND
TALENT COMMITTEE
| | Members of the Compensation and Talent Committee | | | | | | Santo J. Costa | | | L. Patrick Gage | | | Sandford D. Smith | | | Wendell Wierenga Dated: March 31, 2017
Compensation Committee Interlocks and Insider Participation
During fiscal year 2016, directors Santo J. Costa, L. Patrick Gage, Sandford D. Smith and Wendell Wierenga served on the Compensation and Talent Committee. No
|
Compensation Committee Interlocks and Insider Participation During 2018, no current or former member of the Compensation and Talent Committee or Named Executive Officer served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation and Talent Committee. The current and former members of the Compensation and Talent Committee were not officers or employees of the Company while a member of the Compensation and Talent Committee during 2018. Risk Analysis of the Compensation Programs The Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on us. The design of our compensation policies and programs is intended to encourage our employees to remain focused on both our short- and long-term goals. For example, while our cash bonus plans measure corporate and individual performance on an annual basis, the stock options typically vest over a number of years, which the Committee believes encourages employees to focus on sustained stock price appreciation, thus limiting the potential value of excessive risk-taking. Summary Compensation Table The following table summarizes the total compensation earned by or paid to each Named Executive Officer for the fiscal years ended December 31, 2018, 2017 and 2016: Name and Principal Position | | Year | | | Salary(1) | | | Bonus | | | Stock Awards(2) | | | Option Awards(2) | | | All Other Compensation(3) | | | Total | | Mr. Blum, Principal Executive Officer | | | 2018 | | | $ | 630,375 | | | $ | 295,200 | | | $ | 780,000 | | | $ | 1,560,000 | | | $ | — | | | $ | 3,265,575 | | | | | 2017 | | | $ | 611,667 | | | $ | 350,000 | | | $ | 431,586 | | | $ | 1,474,586 | | | $ | — | | | $ | 2,867,838 | | | | | 2016 | | | $ | 591,667 | | | $ | 350,000 | | | $ | — | | | $ | 1,236,290 | | | $ | — | | | $ | 2,177,957 | | Mr. Cragg, Chief Human Resources and Administration Officer | | | 2018 | | | $ | 333,320 | | | $ | 91,663 | | | $ | 234,000 | | | $ | 312,000 | | | $ | 9,014 | | | $ | 979,998 | | | | | 2017 | | | $ | 315,907 | | | $ | 101,129 | | | $ | 212,000 | | | $ | 212,000 | | | $ | 8,901 | | | $ | 849,937 | | | | | 2016 | | | $ | 305,990 | | | $ | 92,903 | | | $ | — | | | $ | 247,258 | | | $ | 8,839 | | | $ | 654,990 | | Mr. Jaw, Principal Financial Officer | | | 2018 | | | $ | 415,125 | | | $ | 67,650 | | | $ | 156,000 | | | $ | 312,000 | | | $ | 3,177 | | | $ | 953,952 | | | | | 2017 | | | $ | 212,884 | | | $ | 125,000 | | | $ | — | | | $ | 611,130 | | | $ | 150,875 | | | $ | 1,099,890 | | Dr. Malik, Executive Vice President, Research and Development | | | 2018 | | | $ | 474,765 | | | $ | 150,535 | | | $ | 312,000 | | | $ | 585,000 | | | $ | 8,700 | | | $ | 1,531,000 | | | | | 2017 | | | $ | 460,937 | | | $ | 175,000 | | | $ | 215,793 | | | $ | 359,655 | | | $ | 8,550 | | | $ | 1,219,935 | | | | | 2016 | | | $ | 447,866 | | | $ | 170,884 | | | $ | — | | | $ | 449,560 | | | $ | 7,950 | | | $ | 1,076,260 | |
(1) | Includes amounts earned but deferred pursuant to our 401(k) plan at the election of the Compensation and Talent Committee or executive officer ofNamed Executive Officers. |
(2) | Reflects the Company has served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation and Talent Committee. The current and former members of the Compensation and Talent Committee were not officers or employees of the Company while a member of the Compensation and Talent Committee during fiscal year 2016. Risk Analysis of the Compensation Programs
The Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on us. The design of our compensation policies and programs is intended to encourage our employees to remain focused on both our short- and long-term goals. For example, while our cash bonus plans measure corporate and individual performance on an annual basis, the stock options typically vest over a number of years, which the Committee believes encourages employees to focus on sustained stock price appreciation, thus limiting the potentialgrant date fair value of excessive risk-taking.
EXECUTIVE COMPENSATION
Summary Compensation Table
The following table summarizes the total compensation earned by or paid to each of the named executive officersRSUs and Option granted. Assumptions used for the fiscal years ended December 31, 2016, 2015 and 2014:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Name and Principal Position | | Year | | | Salary(1) | | | Bonus(2) | | | Stock Awards(3) | | | Option Awards(4) | | | All Other Compensation(5) | | | Total | | Robert I. Blum President and Chief Executive Officer | | | 2016 | | | $ | 591,667 | | | $ | 350,000 | | | | — | | | $ | 1,236,290 | | | | — | | | $ | 2,177,957 | | | | 2015 | | | $ | 571,667 | | | $ | 310,500 | | | $ | 1,259,820 | | | $ | 1,122,380 | | | | — | | | $ | 3,264,367 | | | | 2014 | | | $ | 555,000 | | | $ | 323,010 | | | | — | | | $ | 1,310,900 | | | | — | | | $ | 2,188,910 | | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | | | 2016 | | | $ | 411,120 | | | $ | 156,863 | | | | — | | | $ | 404,604 | | | $ | 7,950 | | | $ | 980,537 | | | | 2015 | | | $ | 402,730 | | | $ | 144,983 | | | $ | 524,925 | | | $ | 420,893 | | | $ | 7,950 | | | $ | 1,501,481 | | | | 2014 | | | $ | 400,775 | | | $ | 153,886 | | | | — | | | $ | 458,815 | | | $ | 7,800 | | | $ | 1,021,276 | | Fady Malik, M.D., Ph.D. Executive Vice President, Research and Development | | | 2016 | | | $ | 447,866 | | | $ | 170,884 | | | | — | | | $ | 449,560 | | | $ | 7,950 | | | $ | 1,076,260 | | | | 2015 | | | $ | 415,891 | | | $ | 157,941 | | | $ | 699,900 | | | $ | 561,190 | | | $ | 7,950 | | | $ | 1,842,872 | | | | 2014 | | | $ | 384,583 | | | $ | 131,891 | | | | — | | | $ | 655,450 | | | $ | 7,800 | | | $ | 1,179,724 | | Bradley P. Morgan, Ph.D. (6) Senior Vice President, Research andNon-Clinical Development | | | 2016 | | | $ | 330,614 | | | $ | 110,465 | | | | — | | | $ | 224,780 | | | $ | 7,950 | | | $ | 673,809 | | | | 2015 | | | $ | 307,142 | | | $ | 88,782 | | | $ | 419,940 | | | $ | 168,357 | | | $ | 7,950 | | | $ | 992,171 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Andrew Wolff, M.D. Senior Vice President, Chief Medical Officer | | | 2016 | | | $ | 394,467 | | | $ | 100,000 | | | | — | | | $ | 179,824 | | | | — | | | $ | 674,291 | | | | 2015 | | | $ | 388,000 | | | $ | 90,000 | | | $ | 349,950 | | | $ | 196,417 | | | | — | | | $ | 1,024,367 | | | | 2014 | | | $ | 388,000 | | | $ | 85,000 | | | | — | | | | — | | | | — | | | $ | 473,000 | |
(1) | Includes amounts earned but deferred at the election of the named executive officers pursuant to our 401(k) employee savings and retirement plan.
|
(2) | Represents amounts earned in 2016 pursuant to our Employee Bonus Plan and paid on March 10, 2017.
|
(3) | Amounts in this column reflect the grant date fair value of PSUs granted pursuant to our equity incentive plans calculated in accordance with the accounting guidance for stock compensation. Assumptions used for the valuation of performance units are set forth in Note 11 to our audited financial statements for the fiscal year ended December 31, 2016, included in our Annual Report on Form10-K for each of such years.
|
(4) | Amounts in this column reflect the grant date fair value of awards granted pursuant to our equity incentive plans, calculated in accordance with the accounting guidance for stock compensation. Assumptions used for the valuation of optionvaluation of these grants are set forth in Note 11 to our audited financial statements for each of the fiscal years ended December 31, 2016, 2015 and 2014, included in our Annual Report on Form10-K for each of such years.
|
(5) | Represents matching contributions under the Company’s 401(k) plan.
|
(6) | Dr. Morgan was became an executive officer of the Company in 2015 and therefore has no compensation disclosed for 2014.
|
Employment and Other Agreements
We have entered into Executive Employment Agreements with each named executive officer.
The Executive Employment Agreements provide for such officers to remainat-will employees of the Company and to receive salary, bonus and benefits as determined at the discretion of the Board of Directors. Such agreements also provide for such officers to receive certain benefits if, within the eighteen-month period following a change of control of the Company, they resign for good reason or are terminated by us or our successor other than for cause — see “Potential Payments Upon Change of Control” below.
EXECUTIVE COMPENSATION
Grants of Plan Based Awards in 2016
The following table sets forth information regarding plan-based awards to each of the named executive officers during 2016.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Estimated Future Payouts Under Employee Bonus Plan(1) | | | All Other Option Awards: Number of Securities Underlying Options (#)(2) | | | Exercise or Base Price of Option Awards ($) | | | Grant Date Fair Value of Stock and Option Awards ($) | | Name | | Grant Date | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | | | Robert I. Blum | | | | | | $ | 0 | | | $ | 357,000 | | | $ | 428,400 | | | | — | | | | — | | | | — | | | | | 02/23/16 | | | | — | | | | — | | | | — | | | | 275,000 | | | $ | 6.67 | | | $ | 1,236,290 | | Sharon A. Barbari | | | | | | $ | 0 | | | $ | 165,119 | | | $ | 198,143 | | | | — | | | | — | | | | — | | | | | 02/23/16 | | | | — | | | | — | | | | — | | | | 90,000 | | | $ | 6.67 | | | $ | 404,604 | | Fady I. Malik, M.D., Ph.D. | | | | | | $ | 0 | | | $ | 179,878 | | | $ | 215,853 | | | | — | | | | — | | | | — | | | | | 02/23/16 | | | | — | | | | — | | | | — | | | | 100,000 | | | $ | 6.67 | | | $ | 449,560 | | Bradley P. Morgan, Ph.D. | | | | | | $ | 0 | | | $ | 116,279 | | | $ | 139,535 | | | | — | | | | — | | | | — | | | | | 02/23/16 | | | | — | | | | — | | | | — | | | | 50,000 | | | $ | 6.67 | | | $ | 224,780 | | Andrew A. Wolff, M.D. | | | | | | $ | 0 | | | $ | 138,516 | | | $ | 166,219 | | | | — | | | | — | | | | — | | | | | 02/23/16 | | | | — | | | | — | | | | — | | | | 40,000 | | | $ | 6.67 | | | $ | 179,824 | |
(1) | Reflects each named executive officer’s participation in our Employee Bonus Plan, calculated based on each officer’s respective base salary and position as of December 31, 2016. Amounts actually earned under the plan in 2016, if any, are reflected in the Summary Compensation Table above.
|
(2) | All stock options granted to the named executive officers in 2016 were granted under the Amended and Restated 2004 Equity Incentive Plan. Each option vests monthly over a four-year period.
|
EXECUTIVE COMPENSATION
Outstanding Equity Awards at December 31, 2016
The following table sets forth information regarding outstanding equity awards held by each named executive officer as of December 31, 2016.
| | | | | | | | | | | | | | | | | | | | | | | | | | | Option Awards | | | Stock Awards | | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units That Have Not Vested(2) | | | Market Value of Shares or Units That Have Not Vested(2) | | | | Exercisable | | | Unexercisable(1) | | | | | | Robert I. Blum | | | 41,666 | | | | — | | | $ | 40.86 | | | | 03/14/2017 | | | | | | | | | | | | | 33,333 | | | | — | | | $ | 20.22 | | | | 02/28/2018 | | | | | | | | | | | | | 45,832 | | | | — | | | $ | 11.10 | | | | 02/26/2019 | | | | | | | | | | | | | 45,000 | | | | — | | | $ | 18.48 | | | | 02/24/2020 | | | | | | | | | | | | | 83,332 | | | | — | | | $ | 9.42 | | | | 02/28/2021 | | | | | | | | | | | | | 74,999 | | | | — | | | $ | 6.30 | | | | 03/05/2022 | | | | | | | | | | | | | 125,000 | | | | 8,333 | | | $ | 6.00 | | | | 03/05/2023 | | | | | | | | | | | | | 141,666 | | | | 58,334 | | | $ | 9.65 | | | | 02/24/2024 | | | | | | | | | | | | | 91,667 | | | | 108,333 | | | $ | 7.96 | | | | 02/26/2025 | | | | | | | | | | | | | 57,291 | | | | 217,709 | | | $ | 6.67 | | | | 02/23/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 180,000 | | | $ | 2,187,000 | | Sharon A. Barbari | | | 9,999 | | | | — | | | $ | 40.86 | | | | 03/14/2017 | | | | | | | | | | | | | 20,499 | | | | — | | | $ | 20.22 | | | | 02/28/2018 | | | | | | | | | | | | | 25,000 | | | | — | | | $ | 11.10 | | | | 02/26/2019 | | | | | | | | | | | | | 22,499 | | | | — | | | $ | 18.48 | | | | 02/24/2020 | | | | | | | | | | | | | 33,332 | | | | — | | | $ | 9.42 | | | | 02/28/2021 | | | | | | | | | | | | | 29,166 | | | | — | | | $ | 6.30 | | | | 03/05/2022 | | | | | | | | | | | | | 46,875 | | | | 3,124 | | | $ | 6.00 | | | | 03/05/2023 | | | | | | | | | | | | | 49,583 | | | | 20,417 | | | $ | 9.65 | | | | 02/24/2024 | | | | | | | | | | | | | 34,375 | | | | 40,625 | | | $ | 7.96 | | | | 02/26/2025 | | | | | | | | | | | | | 18,750 | | | | 71,250 | | | $ | 6.67 | | | | 02/23/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 75,000 | | | $ | 911,250 | | Fady I. Malik, M.D., Ph.D. | | | 3,299 | | | | — | | | $ | 40.86 | | | | 03/14/2017 | | | | | | | | | | | | | 3,134 | | | | — | | | $ | 20.22 | | | | 02/28/2018 | | | | | | | | | | | | | 6,666 | | | | — | | | $ | 11.10 | | | | 02/26/2019 | | | | | | | | | | | | | 8,333 | | | | — | | | $ | 18.48 | | | | 02/24/2020 | | | | | | | | | | | | | 12,500 | | | | — | | | $ | 9.42 | | | | 02/28/2021 | | | | | | | | | | | | | 29,166 | | | | — | | | $ | 6.30 | | | | 03/05/2022 | | �� | | | | | | | | | | | 46,875 | | | | 3,125 | | | $ | 6.00 | | | | 03/05/2023 | | | | | | | | | | | | | 70,833 | | | | 29,167 | | | $ | 9.65 | | | | 02/24/2024 | | | | | | | | | | | | | 45,833 | | | | 54,167 | | | $ | 7.96 | | | | 02/26/2025 | | | | | | | | | | | | | 20,833 | | | | 79,167 | | | $ | 6.67 | | | | 02/23/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 100,000 | | | $ | 1,215,000 | |
EXECUTIVE COMPENSATION
| | | | | | | | | | | | | | | | | | | | | | | | | | | Option Awards | | | Stock Awards | | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units That Have Not Vested(2) | | | Market Value of Shares or Units That Have Not Vested(2) | | | | Exercisable | | | Unexercisable(1) | | | | | | Morgan Bradley, Ph.D. | | | 3,299 | | | | — | | | $ | 40.86 | | | | 03/14/2017 | | | | | | | | | | | | | 3,134 | | | | — | | | $ | 20.22 | | | | 02/28/2018 | | | | | | | | | | | | | 6,666 | | | | — | | | $ | 11.10 | | | | 02/26/2019 | | | | | | | | | | | | | 8,332 | | | | — | | | $ | 18.48 | | | | 02/24/2020 | | | | | | | | | | | | | 12,500 | | | | — | | | $ | 9.42 | | | | 02/28/2021 | | | | | | | | | | | | | 14,999 | | | | — | | | $ | 6.30 | | | | 03/05/2022 | | | | | | | | | | | | | 23,437 | | | | 1,562 | | | $ | 6.00 | | | | 03/05/2023 | | | | | | | | | | | | | 21,250 | | | | 8,750 | | | $ | 9.65 | | | | 02/24/2024 | | | | | | | | | | | | | 13,750 | | | | 16,250 | | | $ | 7.96 | | | | 02/26/2025 | | | | | | | | | | | | | 10,416 | | | | 39,584 | | | $ | 6.67 | | | | 02/23/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 60,000 | | | $ | 729,000 | | Andrew Wolff, M.D. | | | 9,166 | | | | — | | | $ | 40.86 | | | | 03/14/2017 | | | | | | | | | | | | | 20,832 | | | | — | | | $ | 20.22 | | | | 02/28/2018 | | | | | | | | | | | | | 21,666 | | | | — | | | $ | 11.10 | | | | 02/26/2019 | | | | | | | | | | | | | 22,500 | | | | — | | | $ | 18.48 | | | | 02/24/2020 | | | | | | | | | | | | | 33,332 | | | | — | | | $ | 9.42 | | | | 02/28/2021 | | | | | | | | | | | | | 7,291 | | | | — | | | $ | 6.30 | | | | 03/05/2022 | | | | | | | | | | | | | 39,062 | | | | 2,604 | | | $ | 6.00 | | | | 03/05/2023 | | | | | | | | | | | | | 16,042 | | | | 18,958 | | | $ | 7.96 | | | | 02/26/2025 | | | | | | | | | | | | | 8,333 | | | | 31,667 | | | $ | 6.67 | | | | 02/23/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000 | | | $ | 607,500 | |
(1) | All currently unexercisable options in this table vest monthly over a four-year period from the date of grant.
|
(2) | The performance stock units have specific clinical development milestone vesting triggers as well as additional time based vesting conditions. Vesting of 25% occurs March 31, 2017, 50% occurs March 31, 2018 and 25% on March 31, 2019, and only upon Compensation Committee certification of performance achievement. No stock units are earned if the goals are not met. The market value of the stock units is based on the closing stock price of $12.15 per share of our Common Stock as of December 31, 2016.
|
Option Exercises and Vesting of Stock in 2016
There were no stock options exercised and no stock awards vested during the fiscal year ending December 31, 2016.
Pension Benefits
We do not provide our employees, including our named executive officers, with a defined benefit pension plan or any supplemental executive retirement plans or retiree health benefits.
Nonqualified Deferred Compensation
We do not have a nonqualified defined contribution plan or other nonqualified deferred compensation plan.
Potential Payments Upon Termination or Change of Control
We have entered into Executive Employment Agreements with each of the named executive officers. Such agreements provide for such officers to receive certain benefits if, within the eighteen-month period following a change of control of the Company, the executive officer resigns for good reason or is terminated by us or our successor other than for cause (a “qualifying resignation or termination”) and such officer signs a standard release of claims with us. In addition, our executives will receive accelerated vesting of equity awards upon a change of control in which the acquirer does not assume all equity awards. However, we do not have any other agreements, plans or arrangements that provide for severance or other benefits upon termination for other reasons.
EXECUTIVE COMPENSATION
“Good reason” includes a material reduction in salary; a material decrease in duties or responsibilities; a material decrease in the duties or responsibilities of the supervisor to whom the executive officer is required to report; a material decrease in the budget over which the executive officer has authority; relocation of the place of employment to a location more than fifty miles from our location at the time of the change in control; or a material breach of the Executive Employment Agreement by us or our successor.
“Cause” includes failure to substantially perform the duties of the job other than due to physical or mental illness; engaging in conduct that is materially injurious to us or constitutes gross misconduct; material breach of the Executive Employment Agreement by the executive officer; material breach of Company policies that have been adopted by the Board of Directors; conviction of a felony; or fraud against us.
Under their Executive Employment Agreements, upon a qualifying resignation or termination, Ms. Barbari, Dr. Malik, Dr. Morgan and Dr. Wolff will become entitled to receive: continuing severance payments at a rate equal to their base salary for a period of eighteen months; a lump sum payment equal to their full target annual bonus; acceleration in full of vesting of equity awards held by them; and continued employee benefits until the earlier of eighteen months following the date of termination or resignation or the date they obtain employment with generally similar employee benefits. In the event that such payments constitute “parachute payments” within the meaning of Section 280G of the Code and become subject to the excise tax imposed under Section 4999 of the Code, the Executive Employment Agreements of Ms. Barbari, Dr. Malik, Dr. Morgan and Dr. Wolff each provide that the benefit amount may be reduced so that no portion of the payment is subject to the excise tax.
Under his Executive Employment Agreement, upon a qualifying resignation or termination, Mr. Blum will become entitled to receive: continuing severance payments at a rate equal to his base salary for a period of twenty-four months; a lump sum payment equal to his full target annual bonus; acceleration in full of vesting of equity awards held by him; and continued employee benefits until the earlier of twenty-four months following the date of termination or resignation or the date he obtains employment with generally similar employee benefits. In the event that such payments constitute “parachute payments” within the meaning of Section 280G of the Code and become subject to the excise tax imposed under Section 4999 of the Code, Mr. Blum is eligible to receive a payment from us sufficient to pay the excise tax, and a taxgross-up payment, which is an additional payment sufficient to pay the excise tax and other income taxes resulting from the initial excise tax payment. This excise tax and taxgross-up payment has been a benefit we have historically offered at the Chief Executive Officer level based on the uniqueness and importance of that role to our business.
The provisions of each Executive Employment Agreement are intended to comply with the requirements of Section 409A so that none of the severance payments or benefits to be provided under the agreements will be subject to the additional tax imposed under Section 409A. If severance payments to an executive officer at the time of termination would trigger the additional tax imposed under Section 409A, then such payments will instead become payable to the executive officer starting six months and one day after the termination date.
Severance payments and benefits provided to an executive officer under an Executive Employment Agreement following a qualifying resignation or termination are subject to certain conditions including adherence to existing confidentiality, proprietary information and invention assignment agreements, andnon-competition clauses.
The following table summarizes the potential benefits the named executive officers would receive in the circumstances described above assuming their employment had been terminated on December 31, 2016:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Name | | Salary | | | Bonus | | | Acceleration of Vesting of Performance Stock Units(1) | | | Acceleration of Vesting of Stock Options(2) | | | Continuation of Employee Benefits(3) | | | Excise Tax Gross Up(4) | | | Total(5) | | Robert I. Blum | | $ | 1,190,000 | | | $ | 357,000 | | | $ | 2,187,000 | | | $ | 1,844,044 | | | $ | 81,126 | | | $ | 2,292,283 | | | $ | 7,951,453 | | Sharon A. Barbari | | $ | 619,197 | | | $ | 165,119 | | | $ | 911,250 | | | $ | 630,924 | | | $ | 60,479 | | | | — | | | $ | 2,386,969 | | Fady I. Malik, M.D., Ph.D. | | $ | 674,541 | | | $ | 179,878 | | | $ | 1,215,000 | | | $ | 752,931 | | | $ | 60,092 | | | | — | | | $ | 2,882,442 | | Bradley Morgan, Ph. D. | | $ | 498,341 | | | $ | 116,269 | | | $ | 729,000 | | | $ | 316,489 | | | $ | 60,092 | | | | — | | | $ | 1,720,201 | | Andrew Wolff, M.D. | | $ | 593,640 | | | $ | 138,516 | | | $ | 607,500 | | | $ | 268,984 | | | $ | 42,499 | | | | — | | | $ | 1,651,139 | |
(1) | The value of the acceleration of vesting of the PSUs is calculated using the closing market price of the Company’s Common Stock as of December 31, 2016 of $12.15 and assumes all of the performance goals have been met.
|
(2) | The value of the acceleration of vesting of stock options is calculated as the amount by which the closing market price of the Company’s Common Stock as of December 31, 2016 of $12.15 exceeds the exercise price for unvested stock options as of December 31, 2016.
|
(3) | Represents the cost of premiums for medical, dental, vision, life and disability insurance coverage under our group employee benefit plans.
|
(4) | Based on the payment amounts reflected above, Mr. Blum would be subject to excise taxes under Sections 280G and 4999 of the Code. Under his Executive Employment Agreement, Mr. Blum is entitled to receive a payment from the Company sufficient to pay the excise tax, and an excise taxgross-up payment, which is an additional payment sufficient to pay the excise tax and other income taxes resulting from the initial excise tax payment.
|
(5) | Other than Mr. Blum, our named executive officers are not entitled to an excise taxgross-up payment with respect to theirchange-in-control payments and benefits. However, the payments and benefits may be reduced to avoid excise tax if such reduction would enable the executive to net more on anafter-tax basis than they would in the absence of a reduction.
|
DIRECTOR COMPENSATION
Director Summary Compensation Table for 2016
The following table summarizes the total compensation earned by our Directors for the fiscal year ended December 31, 2016.
| | | | | | | | | | | | | Name | | Fees Earned or Paid in Cash ($)(1) | | | Option Awards ($)(1)(2) | | | Total ($) | | Robert I. Blum(3) | | | — | | | | — | | | | — | | Santo J. Costa(4) | | | $57,500 | | | | $101,644 | | | | $159,144 | | L. Patrick Gage, Ph.D.(5) | | | $32,500 | | | | $202,746 | | | | $235,246 | | John T. Henderson, M.B., Ch.B.(6) | | | $25,000 | | | | $160,620 | | | | $185,620 | | Edward M.Kaye.(7) | | | $3,750 | | | | $211,213 | | | | $214,963 | | B. Lynne Parshall, Esq.(8) | | | $45,000 | | | | $131,132 | | | | $176,132 | | Sandford D. Smith(9) | | | $37,500 | | | | $131,132 | | | | $168,632 | | Wendell Wierenga, Ph.D.(10) | | | $52,500 | | | | $131,132 | | | | $183,632 | |
| (1) | Mr. Gage, Dr. Henderson2018 and Dr. Kaye made an annual election to receive 100% of their retainer fee for 2016 in stock options. Ms. Parshall, Mr. Smith and Dr. Wierenga each made an annual election to receive 50% of their retainer fees for 2016 in stock options.
|
| (2) | Amounts in this column reflect the grant date fair value of awards granted in 2016, calculated in accordance with the accounting guidance for stock compensation. Assumptions used for the valuation of option grants are set forth in Note 11 to our audited financial statements for the fiscal year ended December 31, 2016, included in our Annual Report on Form10-K.
|
| (3) | Employee Directors receive no separate compensation for their services as members of the Board of Directors. Refer to summary compensation table, for the employee director’s compensation earned fir the fiscal year ended December 31, 2016.
|
| (4) | As of December 31, 2016, Mr. Costa had outstanding options to purchase 68,331 shares of Common Stock, of which 59,997 were exercisable.
|
| (5) | As of December 31, 2016, Dr. Gage had outstanding options to purchase 169,343 shares of Common Stock, of which 159,759 were exercisable.
|
| (6) | As of December 31, 2016, Dr. Henderson had outstanding options to purchase 146,510 shares of Common Stock, of which 137,446 were exercisable.
|
| (7) | As of December 31, 2016, Dr. Kaye had outstanding options to purchase 40,175 shares of Common Stock, of which 11,117 were exercisable.
|
| (8) | As of December 31, 2016, Ms. Parshall had outstanding options to purchase 84,117 shares of Common Stock, of which 75,418 were exercisable.
|
| (9) | As of December 31, 2016, Mr. Smith had outstanding options to purchase 95,439 shares of Common Stock, of which 86,740 were exercisable.
|
| (10) | As of December 31, 2016, Dr. Wierenga had outstanding options to purchase 91,662 shares of Common Stock, of which 82,963 were exercisable.
|
We reimburse ournon-employee directors Annual Report on Form 10-K for their expenses incurredthe prior three years.
|
(3) | Includes our matching contribution for the Named Executive Officer participation in our 401(k) plan. For Mr. Jaw, includes the compensatory portion of payments to Mr. Jaw in connection with attending Board of Directorsjoining us in June 2017 and committee meetings.related relocation expense. |
34
Outstanding Equity Awards at Fiscal Year-End Table The following table sets forth information regarding outstanding equity awards held by each Named Executive Officer as of December 31, 2018. | | | | | | | Option Awards | | Stock Awards | | Named Executive Officer | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | | Option Expiration Date | | Number of Shares or Units That Have Not Vested | | | | | Market Value of Shares or Units That Have Not Vested(10) | | | | | | | | | Exercisable | | | Unexercisable(9) | | | | | | | | | | | | | | | | | | Robert I. Blum | | 2/26/2009 | | (1 | ) | | | 45,832 | | | | — | | | $ | 11.10 | | | 2/26/2019 | | | | | | | | | | | | | 2/24/2010 | | (1 | ) | | | 45,000 | | | | — | | | $ | 18.48 | | | 2/24/2020 | | | | | | | | | | | | | 2/28/2011 | | (1 | ) | | | 83,332 | | | | — | | | $ | 9.42 | | | 2/28/2021 | | | | | | | | | | | | | 3/5/2012 | | (1 | ) | | | 74,999 | | | | — | | | $ | 6.30 | | | 3/5/2022 | | | | | | | | | | | | | 3/5/2013 | | (1 | ) | | | 133,333 | | | | — | | | $ | 6.00 | | | 3/5/2023 | | | | | | | | | | | | | 2/24/2014 | | (1 | ) | | | 200,000 | | | | — | | | $ | 9.65 | | | 2/24/2024 | | | | | | | | | | | | | 2/26/2015 | | (2 | ) | | | 191,667 | | | | 8,333 | | | $ | 7.96 | | | 2/26/2025 | | | | | | | | | | | | | 2/23/2016 | | (3 | ) | | | 194,791 | | | | 80,209 | | | $ | 6.67 | | | 2/23/2026 | | | | | | | | | | | | | 2/28/2017 | | (4 | ) | | | 93,958 | | | | 111,042 | | | $ | 10.60 | | | 2/28/2027 | | | | | | | | | | | | | 2/27/2018 | | (5 | ) | | | 41,666 | | | | 158,334 | | | $ | 7.80 | | | 2/27/2028 | | | | | | | | | | | | | 2/28/2017 | | (6 | ) | | | | | | | | | | | | | | | | | 36,000 | | | | | $ | 227,520 | | | | 2/27/2018 | | (7 | ) | | | | | | | | | | | | | | | | | 100,000 | | | | | $ | 632,000 | | David W. Cragg | | 2/26/2009 | | (1 | ) | | | 14,166 | | | | — | | | $ | 11.10 | | | 2/26/2019 | | | | | | | | | | | | | 2/24/2010 | | (1 | ) | | | 15,000 | | | | — | | | $ | 18.48 | | | 2/24/2020 | | | | | | | | | | | | | 2/28/2011 | | (1 | ) | | | 16,666 | | | | — | | | $ | 9.42 | | | 2/28/2021 | | | | | | | | | | | | | 3/5/2012 | | (1 | ) | | | 14,999 | | | | — | | | $ | 6.30 | | | 3/5/2022 | | | | | | | | | | | | | 3/5/2013 | | (1 | ) | | | 25,000 | | | | — | | | $ | 6.00 | | | 3/5/2023 | | | | | | | | | | | | | 2/24/2014 | | (1 | ) | | | 45,000 | | | | — | | | $ | 9.65 | | | 2/24/2024 | | | | | | | | | | | | | 2/26/2015 | | (2 | ) | | | 38,333 | | | | 1,667 | | | $ | 7.96 | | | 2/26/2025 | | | | | | | | | | | | | 2/23/2016 | | (3 | ) | | | 38,958 | | | | 16,042 | | | $ | 6.67 | | | 2/23/2026 | | | | | | | | | | | | | 2/28/2017 | | (4 | ) | | | 9,166 | | | | 10,834 | | | $ | 10.60 | | | 2/28/2027 | | | | | | | | | | | | | 2/27/2018 | | (5 | ) | | | 8,333 | | | | 31,667 | | | $ | 7.80 | | | 2/27/2028 | | | | | | | | | | | | | 2/28/2017 | | (6 | ) | | | | | | | | | | | | | | | | | 12,000 | | | | | $ | 75,840 | | | | 2/27/2018 | | (7 | ) | | | | | | | | | | | | | | | | | 30,000 | | | | | $ | 189,600 | | Ching Jaw | | 6/30/2017 | | (8 | ) | | | 28,125 | | | | 46,875 | | | $ | 12.10 | | | 6/30/2027 | | | | | | | | | | | | | 2/27/2018 | | (7 | ) | | | 8,333 | | | | 31,667 | | | $ | 7.80 | | | 2/27/2028 | | | 20,000 | | | | | | 126,400 | | Fady I. Malik, M.D., Ph.D. | | 2/24/2010 | | (1 | ) | | | 8,333 | | | | — | | | $ | 18.48 | | | 2/24/2020 | | | | | | | | | | | | | 2/28/2011 | | (1 | ) | | | 12,500 | | | | — | | | $ | 9.42 | | | 2/28/2021 | | | | | | | | | | | | | 3/5/2012 | | (1 | ) | | | 29,166 | | | | — | | | $ | 6.30 | | | 3/5/2022 | | | | | | | | | | | | | 3/5/2013 | | (1 | ) | | | 50,000 | | | | — | | | $ | 6.00 | | | 3/5/2023 | | | | | | | | | | | | | 2/24/2014 | | (1 | ) | | | 100,000 | | | | — | | | $ | 9.65 | | | 2/24/2024 | | | | | | | | | | | | | 2/26/2015 | | (2 | ) | | | 95,833 | | | | 4,167 | | | $ | 7.96 | | | 2/26/2025 | | | | | | | | | | | | | 2/23/2016 | | (3 | ) | | | 70,833 | | | | 29,167 | | | $ | 6.67 | | | 2/23/2026 | | | | | | | | | | | | | 2/28/2017 | | (4 | ) | | | 22,916 | | | | 27,084 | | | $ | 10.60 | | | 2/28/2027 | | | | | | | | | | | | | 2/27/2018 | | (5 | ) | | | 15,625 | | | | 59,375 | | | $ | 6.00 | | | 2/27/2028 | | | | | | | | | | | | | 2/28/2017 | | (6 | ) | | | | | | | | | | | | | | | | | 18,000 | | | | | $ | 113,760 | | | | 2/27/2018 | | (7 | ) | | | | | | | | | | | | | | | | | 40,000 | | | | | $ | 252,800 | |
Non-employee directors receive a base retainer for service on the Board of Directors and an additional retainer for each committee on which they serve.Non-employee directors no longer receiveper-meeting fees. Annual retainers(1)
| The shares subject to this option are as follows:fully vested. |
(2) | | | | | | | Annual Base Retainer | | Chairman | | $ | 75,000 | | | | Lead outside director (if any) | | $ | 42,500 | | | | Other directors | | $ | 40,000 | | Committee Chairperson Retainer | | Audit Committee | | $ | 20,000 | | | | Compensation and Talent Committee | | $ | 15,000 | | | | Nominating and Governance Committee | | $ | 10,000 | | | | Science and Technology Committee | | $ | 25,000 | | Committee Member Retainer | | Audit Committee | | $ | 10,000 | | | | Compensation and Talent Committee | | $ | 7,500 | | | | Nominating and Governance Committee | | $ | 5,000 | | | | Science and Technology Committee | | $ | 7,500 | |
| DIRECTOR COMPENSATION
Each independent outside director may continue to make an annual election to receive his or her annual base retainerThe unvested shares vest in cash or to receive either 50% or 100%equal monthly installments through 2/26/2019.
|
(3) | The unvested shares vest in equal monthly installments through 2/23/2020. |
(4) | The unvested shares vest in equal monthly installments through 2/28/2021. |
(5) | The unvested shares vest in equal monthly installments through 2/27/2022. |
(6) | The unvested shares vest 40% of the retainershares granted on 2/28/2019 and 20% of the shares granted on 2/28/2020. |
(7) | The unvested stock award vest 40% of the shares granted on 2/28/2019, 40% of the shares granted on 2/28/2020 and 20% of the shares granted on 2/28/2021. |
(8) | The unvested shares vest in stock options. equal monthly installments through 6/30/2021. |
(9) | Unvested Option and Stock Awards are subject to accelerated vesting upon a qualifying resignation or termination as set forth in the executive officer’s employment agreement with us |
(10) | The grant datemarket value of the stock optionsunits that have not yet vested is based on the first businessclosing stock price of $6.32 per share of our Common Stock on December 31, 2018. |
35
Grants of Plan Based Awards in 2018 The following table sets forth information regarding plan-based awards each Named Executive Officer during 2018. | | | | Estimated Future Payouts Under Employee Bonus Plan (1) | | | All Other Stock Awards: Number of shares of stock or units (#) | | | All Other Option Awards: Number of Securities Underlying Options (2) (#) | | | Exercise or Base Price of Option Awards ($) | | | Grant Date Fair Value of Stock and Option Awards(3) ($) | | Named Executive Officer | | Grant Date | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | | | | | | | | | | | | Robert I. Blum | | | | $ | 0 | | | $ | 380,070 | | | $ | 456,084 | | | | | | | | | | | | | | | | | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | 100,000 | | | | | | | $ | 7.80 | | | $ | 780,000 | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | | | | | 200,000 | | | $ | 7.80 | | | $ | 1,560,000 | | David W. Cragg | | | | | | | | $ | 117,773 | | | $ | 141,328 | | | | | | | | | | | | | | | | | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | 30,000 | | | | | | | $ | 7.80 | | | $ | 234,000 | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | | | | | 40,000 | | | $ | 7.80 | | | $ | 312,000 | | Ching Jaw | | | | $ | 0 | | | $ | 166,460 | | | $ | 199,752 | | | | | | | | | | | | | | | | | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | 20,000 | | | | | | | $ | 7.80 | | | $ | 156,000 | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | | | | | 40,000 | | | $ | 7.80 | | | $ | 312,000 | | Fady I. Malik, M.D., Ph.D. | | | | $ | 0 | | | $ | 190,832 | | | $ | 228,999 | | | | | | | | | | | | | | | | | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | 40,000 | | | | | | | $ | 7.80 | | | $ | 312,000 | | | | 2/27/2018 | | | — | | | | — | | | | — | | | | | | | | 75,000 | | | $ | 7.80 | | | $ | 585,000 | |
(1) | Reflects each Named Executive Officer’s participation in our Employee Bonus Plan, calculated based on each officer’s respective base salary and position. Amounts actually earned under this plan are reflected in the Summary Compensation Table. |
(2) | Options granted under the 2004 EIP that vest over a four-year period beginning on the Grant Date. |
(3) | Equal to the number of awards multiplied by the closing trading price of our common stock on the Grant Date. |
Option Exercises and Vesting of Stock in 2018 | | Option Awards | | | Performance Awards | | Named Executive Officer | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting(1) (#) | | | Value Realized on Vesting ($) | | Robert I. Blum | | | — | | | | — | | | | 69,000 | | | | 534,750 | | David W. Cragg | | | — | | | | — | | | | 23,000 | | | | 178,250 | | Ching Jaw | | | — | | | | — | | | | — | | | | — | | Fady I. Malik, M.D., Ph.D. | | | — | | | | — | | | | 37,000 | | | | 286,750 | |
(1) | Equal to the closing trading price of our common stock on the day of vesting multiplied by the fiscal calendar year. The number of stock optionsshares released on vesting. |
Executive Employment and Other Agreements We have Executive Employment Agreements with each Named Executive Officer that provide for such officers to remain at-will employees and to receive salary, bonus and benefits as determined at the discretion of the Board of Directors for such officers to receive certain benefits if, within the eighteen-month period following a change of control of the Company, they resign for good reason or are terminated by us or our successor other than for cause. See “Potential Payments Upon Change of Control” below. Pension Benefits We do not provide our employees, including our Named Executive Officers, with a defined benefit pension plan or any supplemental executive retirement plans or retiree health benefits. Nonqualified Deferred Compensation We do not have a nonqualified defined contribution plan or other nonqualified deferred compensation plan. 36
Potential Payments Upon Termination or Change of Control We have Executive Employment Agreements with each Named Executive Officer that provide for such officers to remain at-will employees and to receive salary, bonus and benefits as determined at the discretion of the Board of Directors for such officers to receive certain benefits if, within the eighteen-month period following a change of control of the Company, they resign for good reason or are terminated by us or our successor other than for cause (a “qualifying resignation or termination”) and such officer signs a standard release of claims with us. In addition, our executives will receive accelerated vesting of equity awards upon a change of control in which the acquirer does not assume all equity awards. However, we do not have any other agreements, plans or arrangements that provide for severance or other benefits upon termination for other reasons. “Good reason” includes a material reduction in salary; a material decrease in duties or responsibilities; a material decrease in the duties or responsibilities of the supervisor to whom the executive officer is required to report; a material decrease in the budget over which the executive officer has authority; relocation of the place of employment to a location more than fifty miles from our location at the time of the change in control; or a material breach of the Executive Employment Agreement by us or our successor. “Cause” includes failure to substantially perform the duties of the job other than due to physical or mental illness; engaging in conduct that is materially injurious to us or constitutes gross misconduct; material breach of the Executive Employment Agreement by the executive officer; material breach of our policies that have been adopted by the Board of Directors; conviction of a felony; or fraud against us. Under their Executive Employment Agreements, upon a qualifying resignation or termination, Mr. Cragg, Mr. Jaw and Dr. Malik will become entitled to receive: continuing severance payments at a rate equal to their base salary for a period of eighteen months; a lump sum payment equal to their full target annual bonus; acceleration in full of vesting of equity awards held by them; and continued employee benefits until the earlier of eighteen months following the date of termination or resignation or the date they obtain employment with generally similar employee benefits. In the event that such payments constitute “parachute payments” within the meaning of Section 280G of the Code and become subject to the excise tax imposed under Section 4999 of the Code, the Executive Employment Agreements of Mr. Cragg, Mr. Jaw and Dr. Malik each provide that the benefit amount may be reduced so that no portion of the payment is subject to the excise tax. Under his Executive Employment Agreement, upon a qualifying resignation or termination, Mr. Blum will become entitled to receive: continuing severance payments at a rate equal to his base salary for a period of twenty-four months; a lump sum payment equal to his full target annual bonus; acceleration in full of vesting of equity awards held by him; and continued employee benefits until the earlier of twenty-four months following the date of termination or resignation or the date he obtains employment with generally similar employee benefits. In the event that such payments constitute “parachute payments” within the meaning of Section 280G of the Code and become subject to the excise tax imposed under Section 4999 of the Code, Mr. Blum is eligible to receive a payment from us sufficient to pay the excise tax, and a tax gross-up payment, which is an additional payment sufficient to pay the excise tax and other income taxes resulting from the initial excise tax payment. This excise tax and tax gross-up payment has been in Mr. Blum’s employment agreement since May 2007, and has been a benefit we have historically offered at the Chief Executive Officer level based on the uniqueness and importance of that role to our business. The provisions of each Executive Employment Agreement are intended to comply with the requirements of Section 409A so that none of the severance payments or benefits to be provided under the agreements will be subject to the additional tax imposed under Section 409A. If severance payments to an executive officer at the time of termination would trigger the additional tax imposed under Section 409A, then such payments will instead become payable to the executive officer starting six months and one day after the termination date. Severance payments and benefits provided to an executive officer under an Executive Employment Agreement following a qualifying resignation or termination are subject to certain conditions including adherence to existing confidentiality, proprietary information and invention assignment agreements, and non-competition clauses. 37
The following table summarizes the potential benefits the Named Executive Officers would receive in the circumstances described above assuming their employment had been terminated on December 31, 2018: Named Executive Officer | | Salary | | | Bonus | | | Acceleration of Vesting of Equity Grants(1) | | | Acceleration of Vesting of Options (1) | | | Continuation of Employee Benefits (2) | | | Total | | Robert I. Blum | | $ | 1,266,900 | | | $ | 380,070 | | | $ | 44,167 | | | $ | 859,520 | | | $ | 96,312 | | | $ | 2,646,968 | | David W. Cragg | | $ | 504,742 | | | $ | 117,773 | | | $ | 8,306 | | | $ | 265,440 | | | $ | 50,647 | | | $ | 946,909 | | Ching Jaw | | $ | 624,225 | | | $ | 166,460 | | | $ | — | | | $ | 126,400 | | | $ | 51,400 | | | $ | 968,485 | | Fady I. Malik, M.D., Ph.D. | | $ | 715,622 | | | $ | 190,832 | | | $ | 16,583 | | | $ | 366,560 | | | $ | 72,236 | | | $ | 1,361,833 | |
(1) | The value of the acceleration of vesting of the equity grants is calculated at a rate of 2.5 timesusing the cash retainer amount, divided by the closing market price of our Common Stock onat December 31, 2018 of $6.32 and the date of grant. For example, if a director elects to receive 100%value of the retainer inacceleration of vesting of options is calculated as the amount by which that closing market price exceeds the exercise price for unvested stock options $100,000 (2.5 times $40,000) is divided byat December 31, 2018. |
(2) | Represents the closing stock price on the date of grant to determine the number of stock options. The stock options vest monthly over aone-year vesting period. This election is not available for the committee retainers. The Company reimburses itsnon-employee directors for theirout-of-pocket expenses incurred in connection with attending Board of Directors and committee meetings.
We have in the past grantednon-employee directors options to purchase our Common Stock pursuant to the terms of our 2004 Equity Incentive Plan and our Board of Directors continues to have the discretion to grant options to new and continuingnon-employee Directors. In May 2015, our Board of Directors and stockholders, respectively, approved our Amended and Restated 2004 Equity Incentive Plan, which provides for automatic grants of stock options to directors who are not our officers or employees. Effective May 20, 2015, new directors received an initial option grant of 35,000 shares on joining the Board of Directors, and continuing directors received an annual option grant 20,000 shares. Generally, grants to new directors vested monthly over three years and grants to continuing directors vest monthly over one year. Also effective May 20, 2015, the timeframe within which anon-employee director resigning from the Board is able to exercise vested options following the resignation date is extended to one year.
Employee directors who meet the eligibility requirements may participate in our 2015 Employee Stock Purchase Plan.
We maintain director and officer indemnification insurance coverage. This insurance covers directors and officers individually. The policies currently run from June 1, 2016 through June 1, 2017 at a total annual cost of $421,502. The primary carrier is Old Republic Insurance Company.
REPORT OF THE AUDIT COMMITTEE
OF THE BOARD OF DIRECTORS
The Audit Committee operatespremiums for medical, dental, vision, life and disability insurance coverage under a written charter adopted by the Board of Directors and reviewed and approved annually by the Audit Committee. The purpose of the Audit Committee is to:our group employee benefit plans.
Select the Company’s independent auditors and oversee the accounting and financial reporting processes of the Company and audits of the financial statements of the Company;
|
Principal Executive Officer Pay Ratio The following table provides the ratio of the total compensation for 2018 for Mr. Blum, our principal executive officer (‟PEO”) to the total compensation for 2018 for our median employee follows: PEO Compensation for 2018 | $ | 3,265,575 | | Median Employee Compensation for 2018 | $ | 226,701 | | Ratio of PEO Compensation to Median Employee Compensation for 2018 | 14 to 1 | |
In determining the median employee, we prepared a listing of all employees using a measurement date of December 31, 2018, annualized the salaries for those employees that were not employed for all of 2018 and identified the employee at the median of the listing of annualized salaries (the “Median Employee”). We calculated the Median Employee Compensation for 2018 for the Median Employee on the same basis as the total compensation of Mr. Blum in the Summary Compensation Table. Equity Compensation Plans at December 31, 2018 The following table provides certain information with respect to all of our equity compensation plans at December 31, 2018. Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | | | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights | | | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans | | | Equity compensation plans approved by stockholders | | | 7,000,537 | | | $ | 8.04 | | | | 2,667,695 | | (1) | Equity compensation plans not approved by stockholders | | | — | | | | — | | | | — | | | | | | 7,000,537 | | | $ | 8.04 | | | | 2,667,695 | | |
Assist the Board of Directors(1)
| The equity compensation plans approved by stockholders are described in oversight and monitoring of (i) the integrity of the Company’sNote 11 to our financial statements (ii) the Company’s financial reporting process, (iii) the Company’s compliance with legal and regulatory requirements under applicable securities law, (iv) the independent auditors’ qualifications, independence and performance, (v) the Company’s systems of internal accounting and financial controls, and (vi) other areas of current or potential risk to the Company’s finances; Provide the Board of Directors with the results of its monitoring and recommendations derived therefrom;
Prepare a report in the Company’s annual proxy statement in accordance with SEC rules; and
Provide to the Board of Directors such additional information and materials as it may deem necessary to make the Board of Directors aware of significant financial matters that come to its attention and that require the attention of the Board of Directors.
Management has the primary responsibility for the financial statements and the reporting process including the system of internal controls.
In fulfilling its responsibilities during 2016, the Audit Committee has:
Reviewed and discussed the audited financial statements and the Company’s financial reporting processes with management;
| • | | Discussed with the Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, matters required to be discussed under Statements of Auditing Standards No. 1301,Communications with Audit Committees, and Statements of Auditing Standards No. 90,Communication with Audit Committees;
|
Received from PricewaterhouseCoopers LLP written disclosures and a letter regarding their independence as required by the rules of the Public Company Accounting Oversight Board, and discussed with PricewaterhouseCoopers LLP their independence from management and the Company; and
Discussed with PricewaterhouseCoopers LLP the overall scope and plans for the audit. The Audit Committee met with PricewaterhouseCoopers LLP, with and without management present, to discuss the results of its examinations, its evaluations of the Company’s internal controls and the overall quality of the Company’s financial reporting.
Based on the foregoing, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Company’sour Annual Report on Form10-K for the year ended December 31, 2016 for filing with the SEC. The Audit Committee and the Board of Directors have also recommended, subject to stockholder ratification, the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017.
| Respectfully submitted,
| MEMBERS OF THE AUDIT COMMITTEE
| B. Lynne Parshall
| John T. Henderson
| Sandford D. Smith
|
Dated: March 31, 2017
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than ten percent of a registered class of our equity2018. Includes 2,414,078 securities to file reports of ownership and changes in ownership with the SEC. Such officers, directors andten-percent stockholders are also required by SEC rules to furnish us with copies of all forms that they file pursuant to Section 16(a). Based solely on its review of the copies of such forms received by it, or written representations from certain reporting persons, we believe that during 2016, our executive officers and directors complied with all applicable filing requirements.
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Review, Approval or Ratification of Transactions with Related Party
Our policy is that any transaction with a related party that is required to be reported under applicable SEC rules, other than compensation-related matters and waivers of our Code of Ethics, must be reviewed and approved according to an established procedure. Such a transaction is reviewed by the Audit Committee as required by the Audit Committee’s charter, and if approved, is then submitted to the full Board of Directors where it is subject to review and approval or ratification by a majority of the independent, disinterested directors. We have not adopted specific standards for approval of these transactions, but instead review each such transaction on acase-by-case basis. Our policy is to require that all such compensation-related matters be reviewed by the Compensation and Talent Committee and, if approved, submitted to the Board of Directors for review and approval. Any waiver of our Code of Ethics must be reviewed by the Nominating and Governance Committee and, if approved, must be reported as required under applicable SEC rules.
Amgen, Inc. (“Amgen”)
In December 2006, the Company entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the “Amgen Agreement”). The agreement granted Amgen an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the development and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to the Company’s development and commercialization participation rights. Amgen reimburses the Company for certain research and development activities it performsavailable under the collaboration.
In June 2013, Cytokinetics2004 EIP and Amgen executed an amendment to the Amgen Agreement to include Japan, resulting in a worldwide collaboration (the “Amgen Agreement Amendment”). Under the terms of the Amgen Agreement Amendment, the Company received anon-refundable upfront license fee of $15.0 million in June 2013. Under the Amgen Agreement Amendment, the Company conducted a Phase 1 pharmacokinetic study intended to support inclusion of Japan in a potential Phase 3 clinical development program and potential global registration dossier253,617 securities available for omecamtiv mecarbil. Amgen reimbursed the Company for the costs of this study. In addition, the Company is eligible to receive additionalpre-commercialization milestone payments relating to the development of omecamtiv mecarbil and royalties on sales of omecamtiv mecarbil in Japan.
In conjunction with the Amgen Agreement Amendment, the Company also entered into a commonissuance under our employee stock purchase agreement which provided for the sale of 1,404,100 shares of its common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. The Company determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was initially deferred and allocated between the license and services based on their relative selling prices using best estimate of selling price. The allocated consideration was recognized as revenue as revenue criteria were satisfied, or as services were performed over approximately 12 months. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company’s common stock.
The Company determined that the license to the Japan territory granted under the Amgen Agreement Amendment was a separate,non-contingent deliverable under the amendment. The Company determined that the license has stand-alone value based on Amgen’s internal product development capabilities since all relevant manufacturingknow-how related to omecamtiv mecarbil was previously delivered to Amgen.
In October 2013, the Company determined that the revenue recognition requirements under ASC605-10 had been met and accordingly, recognized $17.2 million in license revenue attributable to the Amgen Agreement Amendment in the fourth quarter of 2013. In year ended December 31, 2014, the Company recognized the remaining $0.3 million of the previously deferred consideration attributable to the Amgen Agreement Amendment as research and development revenues from related parties.
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Amgen and the Company continued the research program in 2016. Under the amended Amgen Agreement, the Company is entitled to receive reimbursements of internal costs of certain full-time employee equivalents during 2016, as well as potential additional milestone payments related to the research activities.
Under the Amgen Agreement, as amended, the Company is eligible to receive over $300.0 million in additional development milestone payments which are based on various clinical milestones, including the initiation of certain clinical studies, the submission of a drug candidate to certain regulatory authorities for marketing approval and the receipt of such approvals. Additionally, the Company is eligible to receive up to $300.0 million in commercial milestone payments provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments would become due. The achievement of each of these milestones is dependent solely upon the results of Amgen’s development and commercialization activities. During the year ended December 31, 2016, the Company recognized $26.7 million in development milestone payments related to the start ofGALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen. During the years ended December 31, 2015 and 2014, no revenue for milestones achieved under the Amgen Agreement.
The Amgen Agreement also provides for the Company to receive increased royalties byco-funding Phase 3 development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If the Company elects toco-fund such costs at the $40.0 million level, it would be entitled toco-promote theco-funded drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen’s expense.
In July 2013, Amgen announced that it had granted an option to commercialize omecamtiv mecarbil in Europe to Servier, with the Company’s consent, pursuant to an Option, License and Collaboration Agreement (the “Servier Agreement”).
In August 2016, the Company entered into a Letter Agreement with Amgen and Servier (the “Letter Agreement”), which (i) expands the territory of the sublicense to Servier to include specified countries in the Commonwealth of Independent States (“CIS”) and (ii) provides that, if Amgen’s rights under the Amgen Agreement, as amended, are terminated with respect to the territory of such sublicense, the sublicensed rights previously granted by Amgen to Servier under the Servier Agreement will remain in effect and become a direct license or sublicense of such rights by us to Servier, on substantially the same terms as set forth in the Servier Agreement, including but not limited to Servier’s payment of its share of agreed development costs and future milestone and royalty payments to us. The Letter Agreement does not otherwise modify our rights and obligations under the Amgen Agreement, as amended, or create any additional financial obligations of the Company, unless we otherwise agree in writing.
In September 2016, Amgen and Servier announced Servier’s decision to exercise its option to commercialize omecamtiv mecarbil in Europe as well as the CIS, including Russia. The option and related commercialization sublicense to Servier is subject to the terms and conditions of the Amgen Agreement. Amgen remains responsible for the performance of its obligations under the Amgen Agreement relating to Europe and the CIS, including the payment of milestones and royalties relating to the development and commercialization of omecamtiv mecarbil in Europe and the CIS.
In December 2016, the Company provided notice of its exercise of its option under the Amgen Agreement toco-invest in the Phase 3 development program of omecamtiv mecarbil at the level of $10.0 million. In connection with exercising itsco-investment option at $10.0 million, the Company will be eligible to receive an incremental royalty of up to 1% on annual net sales worldwide excluding Japan. The payment of $10.0 million is due to Amgen in eight quarterly installments with the first payment due at the time of providing notice of the option exercise and is contingent on Amgen continuing the Phase 3 development program of omecamtiv mecarbil. As of December 31, 2016, the Company recorded a payment of $1.3 million as a reduction in collaboration revenue, related to the option toco-invest in the Phase 3 development program of omecamtiv mecarbil as a reduction of revenue from Amgen, as it concluded the benefit to be received in exchange for theco-investment payment to Amgen, was not sufficiently separable from Amgen Agreement. In February 2017, the Company provided notice of its further exercise of itsco-invest option in the additional amount of $30.0 million (i.e. to fullyco-invest $40.0 million) in the Phase 3 development program of omecamtiv mecarbil.
Pursuant to the Amgen Agreement, the Company has recognized research and development revenue from Amgen for reimbursements of internal costs of certain full-time employee equivalents, supporting a collaborative research program directed to the discovery of next-generation cardiac sarcomere activator compounds and of other costs related to that research program. These reimbursements were recorded as research and development revenues from related parties. During the years ended December 31, 2016, 2015 and 2014, the Company recorded net research and development revenue from Amgen of $27.9 million, $2.5 million and $4.5 million, respectively, under the Amgen Agreement. There were no accounts receivable due from Amgen during the years ended December 31, 2016 and 2015.
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Revenue from Amgen was as follows (in thousands):
| | | | | | | | | | | | | | | Years Ended December 31, | | | | 2016 | | | 2015 | | | 2014 | | Research and development revenues from related parties, net: | | | | | | | | | | | | | Reimbursement of internal costs | | $ | 2,466 | | | $ | 2,460 | | | $ | 4,260 | | Research and development milestone fees | | | 26,666 | | | | — | | | | — | | Co-invest option payment | | | (1,250 | ) | | | — | | | | — | | Allocated consideration | | | — | | | | 21 | | | | 278 | | | | | | | | | | | | | | | Total Research and development revenues from related parties, net | | | 27,882 | | | | 2,481 | | | | 4,538 | | | | | | | | | | | | | | | Total net revenues from Amgen | | $ | 27,882 | | | $ | 2,481 | | | $ | 4,538 | |
Astellas Pharma, Inc. (“Astellas”)
Original Astellas Agreement(Non-neuromuscular license)
In June 2013, the Company entered into a license and collaboration agreement with Astellas (the “Original Astellas Agreement”). The primary objective of the collaboration with Astellas is to advance novel therapies for diseases and medical conditions associated with muscle weakness.
Under the Original Astellas Agreement, the Company granted Astellas an exclusive license toco-develop and jointly commercializeCK-2127107, a fast skeletal troponin activator, for potential application innon-neuromuscular indications worldwide. The Company was primarily responsible for the conduct of Phase 1 clinical trials and certain Phase 2 readiness activities forCK-2127107 and Astellas was primarily responsible for the conduct of subsequent development and commercialization activities forCK-2127107.
In July 2013, the Company received an upfront,non-refundable license fee of $16.0 million in connection with the execution of the Original Astellas Agreement. Under the agreement, the Company was eligible to potentially receive over $24.0 million in reimbursement of sponsored research and development activities during the initial two years of the collaboration. The Original Astellas Agreement also provided for research and early and late stage development milestone payments based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products, and royalties on sales of commercialized products.
At the inception of the Original Astellas Agreement, the Company deferred revenue related to the Original Astellas Agreement in accordance with ASC605-25. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis. Upfront,non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where this is not the case, the Company does not consider the license deliverable to be a separate unit of accounting, and the revenue for the license fee is deferred and recognized in conjunction with the other deliverables that constitute the combined unit of accounting.
The Company determined that the license and the research and development services are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue using the proportional performance model over the initial research term of the Original Astellas Agreement. During the years ended December 31, 2016, 2015 and 2014, the Company recorded zero, $2.3 million and $9.8 million, respectively, in license revenue based on the proportional performance model under the Original Astellas Agreement. No license revenue remains deferred under the Original Astellas Agreementplan as of December 31, 2016.2018.
Pursuant to the Original Astellas Agreement, the Company recognized research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. During the years ended December 31, 2016, 2015 and 2014, the Company recorded research and development revenue from Astellas of zero, $3.5 million and $15.4 million, respectively, under the Original Astellas Agreement.
2014 Astellas Agreement (Expansion to include neuromuscular indications)
In December 2014, the Company entered into an amended and restated license and collaboration agreement with Astellas (the “2014 Astellas Agreement”). This agreement superseded the Original Astellas Agreement. The 2014 Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to include spinal muscular atrophy (SMA) and potentially other neuromuscular indications forCK-2127107 and other fast skeletal troponin activators, in addition to thenon-neuromuscular indications provided for in the Original Astellas Agreement.
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Under the 2014 Astellas Agreement, the Company received anon-refundable upfront license fee of $30.0 million in January 2015. Concurrently, the Company received $15.0 million as a milestone payment relating to Astellas’ decision to advanceCK-2127107 into Phase 2 clinical development. Under the 2014 Astellas Agreement, the Company is conducting the initial Phase 2 clinical trial ofCK-2127107 in patients with SMA.
The Company determined that the license and the research and development services relating to the 2014 Astellas Agreement are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue over the research term of the 2014 Astellas Agreement using the proportional performance model.
During the years ended December 31, 2016 and 2015, the Company recorded $12.1 million and $11.6 million, respectively, in license revenue based on the proportional performance model under the 2014 Astellas Agreement. No such revenues were recognized during the year ended December 31, 2014. As of December 31, 2016, $7.2 million license revenue remains deferred under the 2014 Astellas Agreement. Pursuant to the 2014 Astellas Agreement, the Company recognized research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. The Company was eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the two years of the collaboration following the execution of the 2014 Astellas Agreement. During the years ended December 31, 2016 and 2015, the Company recorded research and development revenue from Astellas of $13.0 million and $8.7 million, respectively, under the 2014 Astellas Agreement. No such revenues were recognized during the year ended December 31, 2014.
In conjunction with the 2014 Astellas Agreement, the Company also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to the Company’s common stock. The Company determined the fair value of the stock issued to Astellas to be $9.1 million. The excess of cash received over fair value of $0.9 million was deferred along with the license and research and development services. Allocated consideration will be recognized as revenue for the single unit of accounting above, as services are performed following the proportional performance model over the research term of the 2014 Astellas Agreement. Following the common stock purchase, Astellas was determined to be a related party. As such, all revenue earned following the common stock purchase is classified as related party revenue.
2016 Astellas Amendment (Inclusion of ALS as an Added Indication and Option on Tirasemtiv)
In September 2016, the Company and Astellas executed an amendment (the “2016 Amendment”) to expand their collaboration on the research, development and commercialization of skeletal muscle activators under the 2014 Astellas Agreement (collectively, the “Current Astellas Agreement”).
Under the 2016 Astellas Amendment, the Company granted Astellas the Option on Tirasemtiv. If Astellas exercises the option, Astellas will receive exclusive worldwide commercialization rights outside of the Company’s commercialization territory of North America, Europe and other select countries. Tirasemtiv is the Company’s fast skeletal troponin activator being evaluated in the ongoing Phase 3 clinical trial,VITALITY-ALS, in people living with amyotrophic lateral sclerosis (“ALS”).
In addition, the 2016 Astellas Amendment expands the Company’s collaboration with Astellas to include the development ofCK-2127107, a next-generation fast skeletal troponin activator, for the potential treatment of ALS, as well the possible development in ALS of other fast skeletal regulatory activators licensed to Astellas under the 2014 Astellas Agreement (“ALS License”). Finally, the 2016 Astellas Amendment extends the existing joint research program focused on the discovery of additional next-generation skeletal muscle activators through 2017, including sponsored research at Cytokinetics.
Astellas’ Option on Tirasemtiv
In connection with the execution of the 2016 Astellas Amendment, the Company received a $15.0 millionnon-refundable option fee for the grant of the Option on Tirasemtiv in October 2016. Prior to Astellas’ exercise of the option, the Company will continue the development of tirasemtiv, including theVITALITY-ALS trial, at its own expense to support regulatory approval in the U.S., EU and certain other jurisdictions and will retain the final decision making authority on the development of tirasemtiv. If Astellas exercises the option, the Company will grant Astellas an exclusive license to develop and commercialize tirasemtiv outside the Company’s own commercialization territory of North America, Europe and other select countries (“License on tirasemtiv”) under a tirasemtiv License and Collaboration Agreement (“tirasemtiv License Agreement”). Each party would be primarily responsible for the further development of tirasemtiv in its territory and have the exclusive right to commercialize tirasemtiv in its territory.
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
If Astellas exercises its option for a global collaboration for the development and commercialization of tirasemtiv, the Company will receive an option exercise payment ranging from $25.0 million (if exercise occurs following receipt of data from theVITALITY-ALS trial) to $80.0 million (if exercise occurs following receipt of FDA approval) and a milestone payment of $30.0 million from Astellas associated with the Company’s initiation of the open-label extension trial for tirasemtiv(VIGOR-ALS). The Company will be responsible for the development costs of tirasemtiv during the option period, but if Astellas exercises the option after the defined review period following receipt of data fromVITALITY-ALS, Astellas will at the time of option exercise reimburse the Company for a share of any additional costs incurred after such review period.
If Astellas exercises the option for tirasemtiv, the parties will share the future development costs of tirasemtiv in North America, Europe and certain other countries (with Cytokinetics bearing 75% of such shared costs and Astellas bearing 25% of such costs), and Astellas will be solely responsible for the development costs of tirasemtiv specific to its commercialization territory. Contingent upon the successful development of tirasemtiv, the Company may receive milestone payments up to $100.0 million for the initial indication and up to $50.0 million for each subsequent indication. If tirasemtiv is commercialized, Astellas will pay the Company royalties (at rates ranging from themid-teens to twenty percent) on sales of tirasemtiv in Astellas’ territory, and the Company will pay Astellas royalties (at rates up to themid-teens) on sales of tirasemtiv in the Company’s territory, in each case subject to various possible adjustments.
The Company concluded that the option to obtain the License on Tirasemtiv is a substantive option, and is therefore not considered a deliverable at the execution of the 2016 Amendment. The Company determined that the Tirasemtiv License Agreement is contingent upon the exercise of the Option on Tirasemtiv, and is therefore not effective during the periods presented, since the option has not been exercised as of the latest balance sheet date. In addition, the Company did evaluate the consideration set to be received for the License on Tirasemtiv in relation to the fair value of the License on tirasemtiv, and determined that it was not being provided at a significant incremental discount.
The Company further determined that the Option Fee of $15.0 million was deemed to be a prepayment towards the License on tirasemtiv, and therefore deferred revenue recognition either until the option is exercised, or until the option expires unexercised. If the Option on Tirasemtiv expires unexercised, the $15.0 million receipt would be added to the 2016 Amendment consideration, to be allocated to the units of accounting. The Option on Tirasemtiv expires, if not exercised by Astellas, following the receipt of the approval letter for tirasemtiv from the FDA.
Prior to Astellas’ exercise of the option, the Company will continue the development of tirasemtiv, including theVITALITY-ALS trial, at its own expense to support regulatory approval in the U.S., EU and certain other jurisdictions, and the Company has complete discretion to continue to conduct clinical trials, and will retain the final decision making authority on the development of tirasemtiv. Therefore, the Company concluded that there was no obligation related to any development services during the option period.
Addition of ALS as an Added Indication(CK-2127107and other fast skeletal activators)
In connection with the execution of the 2016 Astellas Amendment, the Company received anon-refundable upfront amendment fee of $35 million. In addition, the Company received an accelerated $15.0 million milestone payment that would have been payable upon the initiation of the first Phase 2 clinical trial ofCK-2127107 as the lead compound in ALS, as if such milestone had been achieved upon the execution of the 2016 Astellas Amendment.
The Company and Astellas are collaborating to developCK-2127107 in ALS. Astellas is primarily responsible for the development ofCK-2127107 in ALS, but the Company will conduct the Phase 2 clinical trial ofCK-2127107 in ALS and will share in the operational responsibility for later clinical trials. Subject to specified guiding principles, decision making will be by consensus, subject to escalation and, if necessary, Astellas’ final decision making authority on the development (including regulatory affairs), manufacturing, medical affairs and commercialization ofCK-2127107 and other fast skeletal regulatory activators in ALS. The Company and Astellas will share equally the costs of developingCK-2127107 in ALS for potential registration and marketing authorization in the U.S. and Europe, provided that (i) Astellas has agreed to solely fund Phase 2 development costs ofCK-2127107 in ALS subject to a right to recoup the Company’s share of such costs plus a 100% premium by reducing future milestone and royalty payments to the Company and (ii) the Company may defer (but not eliminate) a portion of itsco-funding obligation for development activities after Phase 2 for up to 18 months, subject to certain conditions. The Company has the right toco-fund its share of such Phase 2 development costs on a current basis, in which case there would not be a premium due to Astellas. Cytokinetics will also receive approximately $41.8 million in additional sponsored research and development funding through 2018 which includes Astellas’ funding of Cytokinetics’ conduct of the Phase 2 clinical development ofCK-2127107 in ALS (approximately $36.6 million) as well as the continuing research collaboration (approximately $5.2 million).
Pursuant to the 2016 Astellas Amendment, the Company and Astellas will collaborate to developCK-2127107 in ALS. Astellas will be primarily responsible for the development ofCK-2127107 in ALS, but the Company will conduct the Phase 2
CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
clinical trial ofCK-2127107 in ALS and will share in the operational responsibility for later clinical trials. Subject to specified guiding principles, decision making will be by consensus, subject to escalation and, if necessary, Astellas’ final decision making authority on the development (including regulatory affairs), manufacturing, medical affairs and commercialization ofCK-2127107 and other fast skeletal regulatory activators in ALS.
The Company determined that the deliverables under the 2016 Astellas Amendment included (1) the ALS License,(2) CK-2127107 development services in ALS through Phase 2 activities (“ALS Development Services”), and (3) research services added (“Additional Research Services”). Deliverables that do not provide standalone value have been combined with other deliverables to form a unit of accounting that collectively has standalone value, with revenue being recognized on the combined unit of accounting, rather than the individual deliverables. There are no rights of return provisions for the delivered items in the Current Astellas Agreement.
The Company considered the 2016 Astellas Amendment to be a modification of the 2014 Astellas Agreement. The remaining deliverables under the 2014 Astellas Agreement are: (1) the SMA license; (2) Research Services in connection with the Research Plan (through 2016); and (3) SMA Development Services in connection with the Development Plan. The Company evaluated the components and consideration of the 2016 Astellas Amendment against other Phase 2 collaboration arrangements, and determined that the new 2016 deliverables had standalone value and are delivered at fair value. Therefore no reallocation of consideration to the 2014 deliverables was performed.
The Company concluded that there are two units of accounting; the ALS License, and the Additional Research Services and ALS Development Services (“Research and ALS Development Services”). The Company also determined that the ALS License has standalone value since (1) Astellas received a worldwide license for ALS, to perform further research in the field of ALS, to develop and useCK-2127107 to make, have make, sell or otherwise commercializeCK-2127107 in ALS; (2) Astellas has the right to sublicense the rights toCK-2127107 in ALS to a third party; and (3) Astellas has the technical capabilities to advance further development onCK-2127107 in ALS, without the continued involvement of the Company.
Arrangement Consideration under the 2016 Astellas Amendment related toCK-2127107 and research is comprised of the following (in millions):
|
38
DIRECTOR COMPENSATION Annual Retainers for Service. Non-employee directors receive an annual base retainer for service on the Board of Directors and an additional annual committee retainer for each committee on which they serve. Annual retainers are as follows: Base Retainer | | Board of Directors Chair | | $ | 75,000 | | | | Lead outside director (if any) | | $ | 42,500 | | | | Other directors | | $ | 40,000 | | Committee Chair Retainer | | Audit Committee | | $ | 20,000 | | | | Compensation and Talent Committee | | $ | 15,000 | | | | Nominating and Governance Committee | | $ | 10,000 | | | | Science and Technology Committee | | $ | 25,000 | | Committee Member Retainer | | Audit Committee | | $ | 10,000 | | | | Compensation and Talent Committee | | $ | 7,500 | | | | Nominating and Governance Committee | | $ | 5,000 | | | | Science and Technology Committee | | $ | 7,500 | |
Election to Receive Retainers in Cash or Stock Options. Each non-employee director may make an annual election to receive the annual base retainer (but not committee retainers) either in cash or to receive either 50% or 100% of that retainer in stock options granted on the first business day of a calendar year. The number of stock options granted is calculated at a rate of 2.5 times the cash retainer amount, divided by the closing price of our Common Stock on the date of grant. For example, if a director with $40,000 from the base retainer elects to receive 100% of the retainer in stock options, $100,000 (2.5 times $40,000) is divided by the closing stock price on the date of grant to determine the number of stock options. These stock options vest monthly over twelve months. Automatic Grants to Non-Employee Directors. Under the 2004 EIP, non-employee directors receive automatic grants of stock options. Directors receive an initial option grant of 35,000 shares on joining the Board of Directors. Continuing directors receive an annual option grant 20,000 shares, generally at the time of the Annual Meeting of Stockholders. Generally, an initial grant to a director vests monthly over three years and grants to continuing directors vest monthly over one year. Our Board of Directors continues to have discretion to grant options to new and continuing non-employee directors. A non-employee director that resigns from the Board has one year following resignation to exercise vested options. Director Summary Compensation Table for 2018 Employee directors receive no separate compensation for service as a member of the Board of Directors. The following table summarizes the total compensation for 2018 earned by our non-employee Directors. Name | | Fees Earned or Paid in Cash ($) | | | Option Awards ($) | | | Total ($) | | Dr. Califf | | $ | 20,625 | | | $ | 326,628 | | | $ | 347,253 | | Mr. Costa | | $ | 60,000 | | | $ | 128,314 | | | $ | 266,926 | | Dr. Gage | | $ | 25,000 | | | $ | 255,545 | | | $ | 241,926 | | Dr. Henderson | | $ | 22,500 | | | $ | 196,169 | | | $ | 287,906 | | Dr. Kaye | | $ | 17,500 | | | $ | 196,169 | | | $ | 281,656 | | Ms. Parshall | | $ | 45,000 | | | $ | 162,241 | | | $ | 282,104 | | Mr. Smith | | $ | 37,500 | | | $ | 162,241 | | | $ | 272,729 | | Dr. Wierenga | | $ | 52,500 | | | $ | 162,241 | | | $ | 296,479 | |
Automatic grants of stock options to non-employee directors were granted at the time of the 2018 Annual Meeting at an exercise price of $9.45 per share. As of January 2, 2018, non-employee directors elected to receive stock options in lieu of some or all of their retainers as follows: Dr. Gage – 21,248; Dr. Henderson – 11,428; Dr. Kaye – 11,428; Ms. Parshall – 5,714; Mr. Smith – 5,714; and Dr. Wierenga – 5,714, all at an exercise price of $8.75 per share. On February 8, in connection with joining our Board of Directors, Dr. Califf received options to purchase 35,000 shares at an exercise price of $8.35 per share. Option awards reflect the grant-date fair value of stock options grants. As of December 31, 2018, the aggregate number of stock options held by our non-employee directors were as follows: Dr. Califf – 55,000; Mr. Costa – 98,331; Dr. Gage – 215,771; Dr. Henderson – 206,002; Dr. Kaye – 99,667; Ms. Parshall – 133,863; Mr. Smith – 145,185; and Dr. Wierenga – 141,408. Assumptions used for the valuation of stock option grants are set forth in Note 11 to our financial statements, included in our Annual Report on Form 10-K 39
for the year ended December 31, 2018. We reimburse our non-employee directors for out-of-pocket expenses incurred in connection with service on our Board of Directors. We maintain director and officer indemnification insurance policies that covers the Company as well as directors and officers individually. The policies currently run from June 1, 2018 through June 1, 2019 at a total annual cost of $560,000. The primary carrier is Old Republic Insurance Company. 40
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS The Audit Committee operates under a written charter adopted by the Board of Directors that is reviewed and approved annually by the Audit Committee. The purpose of the Audit Committee is to: Select our independent auditors and oversee our accounting and financial reporting processes and audits of our financial statements; Assist the Board of Directors in oversight and monitoring of (i) the integrity of our financial statements, (ii) our financial reporting process, (iii) our compliance with legal and regulatory requirements under applicable securities law, (iv) the independent auditors’ qualifications, independence and performance, (v) our systems of internal accounting and financial controls, and (vi) other areas of current or potential risk to our finances; Provide the Board of Directors with the results of the Audit Committee’s monitoring and recommendations derived therefrom; Prepare a report in our annual proxy statement in accordance with SEC rules; and Provide to the Board of Directors such additional information and materials as it may deem necessary to make the Board of Directors aware of significant financial matters that come to its attention and that require the attention of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process including the system of internal controls. In fulfilling its responsibilities during 2018, the Audit Committee has: Reviewed and discussed the audited financial statements and our financial reporting processes with management; Discussed with our independent registered public accounting firm, Ernst & Young LLP, matters required to be discussed under Statements of Auditing Standards No. 1301, Communications with Audit Committees, and Statements of Auditing Standards No. 90, Communication with Audit Committees; Received from Ernst & Young LLP written disclosures and a letter regarding their independence as required by the rules of the Public Company Accounting Oversight Board, and discussed with Ernst & Young LLP their independence from management and us; and Discussed with Ernst & Young LLP the overall scope and plans for the audit. The Audit Committee met with Ernst & Young LLP, with and without management present, to discuss the results of its examinations, its evaluations of our internal controls and the overall quality of our financial reporting. Based on the foregoing, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2018 for filing with the SEC. The Audit Committee and the Board of Directors have also recommended, subject to stockholder ratification, the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019. | | | | | | | Arrangement
Consideration | | Amendment Fee | | | $35.0 | | Accelerated milestone payment | | | 15.0 | | | | | | | Total Upfront Consideration
| | | 50.0 | | Additional Research Services | | | 5.1 | | ALS Development Services | | | 39.1 | | | | | | | Total Committed Consideration
| | | 44.2 | | | | | | | Total Consideration | | | $94.2 | |
The Company allocated the $50.0 million in upfront consideration along with the $44.2 million in then committed research and development consideration, among the two units of accounting, on a relative fair value basis, using the best estimated selling price (“BESP”). The BESP of the ALS License was determined using a discounted cash flow, risk adjusted for probability of success; while the BESP of the research and development services were determined using estimated research and development cost, included in the research and development programs approved by Astellas. Based on this allocation of consideration, the Company stands to recognize $74.9 million in license revenue and $19.3 in research and development revenue, under the 2016 Astellas Amendment. Since the upfront consideration of $50.0 million is less than the allocated consideration of the ALS License, the Company recognized $50.0 million in license revenue on the Amendment Effective Date, in September 2016, and record the remaining $24.9 million as an allocation from research and development services, when those services are performed.
Allocation of arrangement consideration, and revenue recognition (in millions):
| | | | | | | | | | | | | | | Allocated Consideration | | | Upfront Revenue Recognition | | | Revenue Recognition over Performance Period | | Units of Accounting: | | | | | | | | | | | | | ALS License | | $ | 74.9 | | | $ | 50.0 | | | $ | 24.9 | | Research and ALS Development Services | | | 19.3 | | | | — | | | | 19.3 | | | | | | | | | | | | | | | Total consideration | | $ | 94.2 | | | $ | 50.0 | | | $ | 44.2 | |
| | Respectfully submitted, CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
| During the year ended December 31, 2016, the Company recorded $50.1 million in license revenue under the 2016 Astellas Amendment.
The Company will recognize the research and development services using the proportional performance model over the initial development term, through the completion of the ALS Development Services. Pursuant to the 2016 Astellas Amendment, the Company receives payment for research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs.
During the year ended December 31, 2016, the Company recorded $0.1 million research and development revenue from Astellas, under the 2016 Astellas Amendment.
The Company believes that each of the milestones related to research under the Current Astellas Agreement is substantive and can only be achieved with the Company’s past and current performance and each milestone will result in additional payments to the Company. During the year ended December 31, 2016, the Company recorded $2.0 million in milestone revenue for research under this agreement, related to the initiation ofIND-enabling studies for a fast skeletal troponin activator. The Company is eligible to receive up to $2.0 million in research milestone payments under the collaboration for each future potential drug candidate.
The achievement of each of the late stage development milestones and the commercialization milestones are dependent solely upon the results of Astellas’ development activities and therefore these milestones were not deemed to be substantive.
Under the Current Astellas Agreement, additional research and early and late state development milestone payments which are based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products could total over $600.0 million, including up to $95.0 million relating toCK-2127107 innon-neuromuscular indications, and over $100.0 million related toCK-2127107 in each of SMA, ALS and other neuromuscular indications. Additionally, $200.0 million in commercial milestones could be received under the Current Agreement provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due.
In the event Astellas commercializes any collaboration products, the Company will receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containingCK-2127107. Cytokinetics canco-fund certain development costs forCK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. Under the Current Astellas Agreement, Cytokinetics retains an option toco-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to its option toco-promote other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with itsco-promotion activities.
Research and development revenue from Astellas was as follows (in thousands):
| | | | | | | | | | | | | | | | Year Ended December 31, 2016 | | | Year Ended December 31, 2015 | | | Year Ended December 31, 2014 | | License Revenues from Related Parties | | $ | 62,171 | | | $ | 13,918 | | | $ | 9,835 | | Research and development revenues with related parties: | | | | | | | | | | | | | Reimbursement of internal costs | | | 6,111 | | | | 6,210 | | | | — | | Reimbursement of other costs | | | 6,999 | | | | 5,974 | | | | — | | Research and development milestone fees | | | 2,000 | | | | — | | | | 15,000 | | | | | | | | | | | | | | | Total research and development revenue with related parties from Astellas | | $ | 15,110 | | | $ | 12,184 | | | $ | 15,000 | | | | | | | | | | | | | | | Research and development revenues: | | | | | | | | | | | | | Reimbursement of internal costs | | | — | | | | — | | | | 8,939 | | Reimbursement of other costs | | | — | | | | — | | | | 6,452 | | Research and development milestone fees | | | — | | | | — | | | | 2,000 | | | | | | | | | | | | | | | Total research and development revenue from Astellas | | | — | | | | — | | | | 32,391 | | | | | | | | | | | | | | | Total Revenue from Astellas | | $ | 77,281 | | | $ | 26,102 | | | $ | 42,226 | |
| CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
At December 31, 2016 and December 31, 2015, the Company had $23.1 million and $20.4 million, respectively, of deferred revenue under the Current Astellas Agreement, reflecting the unrecognized portion of the license revenue, option fee and payment of expenses. There were no accounts receivable due from Astellas at December 31, 2016 and 2015.
Indemnification of Directors and Officers
The Company provides indemnification for its directors and officers so that they will be free from undue concern about personal liability in connection with their service to the Company. Under the Company’s Bylaws, the Company is required to indemnify its directors and officers to the extent not prohibited under Delaware or other applicable law. We have also entered into indemnification agreements with each of our directors and officers, which require us to indemnify its directors and officers to the fullest extent permitted by Delaware law.
HOUSEHOLDING OF PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
This year, a number of brokers with account holders who are Cytokinetics stockholders will be “householding” the Company’s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify us or your broker. Direct your written request to Investor Relations, Cytokinetics, Incorporated, 280 East Grand Avenue, South San Francisco, California 94080 or contact Investor Relations at650-624-3283. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request “householding” of their communications should contact their brokers.
OTHER MATTERS
The information contained above under the captions “Compensation and Talent Committee Report” and “ReportMembers of the Audit Committee of the Board of Directors” shall not be deemed to be soliciting material or to be filed
| | | B. Lynne Parshall, Esq., Chair | | | John T. Henderson, M.B., Ch.B. Edward M. Kaye, M.D. | | | Sandford D. Smith |
41
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Such officers, directors and ten-percent stockholders are also required by SEC rules to furnish us with copies of all forms that they file pursuant to Section 16(a). Based solely on its review of the copies of such forms received by it, or written representations from certain reporting persons, we believe that during 2018, our officers and directors complied with all applicable filing requirements. CERTAIN BUSINESS RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Review, Approval or Ratification of Transactions with Related Party Our policy is that any transaction with a related party that is required to be reported under applicable SEC rules, other than compensation-related matters and waivers of our Code of Ethics, must be reviewed and approved according to an established procedure. Such a transaction is reviewed by the Audit Committee as required by the Audit Committee’s charter, and if approved, is then submitted to the full Board of Directors where it is subject to review and approval or ratification by a majority of the independent, disinterested directors. We have not adopted specific standards for approval of these transactions, but instead review each such transaction on a case-by-case basis. Our policy is to require that all such compensation-related matters be reviewed by the Compensation and Talent Committee and, if approved, submitted to the Board of Directors for review and approval. Any waiver of our Code of Ethics must be reviewed by the Nominating and Governance Committee and, if approved, must be reported as required under applicable SEC rules. Indemnification of Directors and Officers We provide indemnification for our directors and officers so that they will be free from undue concern about personal liability in connection with their service to us. Under our Bylaws, we are required to indemnify our directors and officers to the extent not prohibited under Delaware or other applicable law. We have also entered into indemnification agreements with each of our directors and officers, which require us to indemnify our directors and officers to the fullest extent permitted by Delaware law. HOUSEHOLDING OF PROXY MATERIALS The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially means extra convenience for stockholders and cost savings for companies. A number of brokers with account holders who are our stockholders will be householding our proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If you no longer wish to participate in householding and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify us or your broker. Direct your written request to Investor Relations, Cytokinetics, Incorporated, 280 East Grand Avenue, South San Francisco, California 94080 or contact Investor Relations at 650-624-3283. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request householding of their communications should contact their brokers. OTHER MATTERS The information contained above under the captions “Compensation and Talent Committee Report” and “Report of the Audit Committee of the Board of Directors” shall not be deemed to be soliciting material or to be filed with the 42
SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing. We know of no other matters to be submitted to the meeting. If any other matters properly come before the meeting, it is the intention of the persons named in the Proxy to vote the shares they represent as the Board of Directors may recommend. | | | THE BOARD OF DIRECTORS | Dated: March 31, 201727, 2019 APPENDIX A
| CYTOKINETICS, INCORPORATED
AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN
AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013
APPROVED BY STOCKHOLDERS: MAY 22, 2013
AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013
AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015
APPROVED BY STOCKHOLDERS: MAY 20, 2015
APPROVED BY STOCKHOLDERS: [MAY 18, 2017]
1. PURPOSES OF THE PLAN AND PERMITTED AWARDS.
The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.
2. SHARES SUBJECT TO THE PLAN.
(a) Shares Subject to the Plan. Subject to adjustments as specified in Section 12 of the Plan, the maximum aggregate number of Shares that may be issued under the Plan is 11,637,190 Shares. The Shares may be authorized, but unissued, or reacquired Stock.
(b) Treatment of Lapsed Awards. To the extent that an Award terminates, expires, or lapses for any reason, any shares of Stock subject to the Award shall again be available for the grant of an Award pursuant to the Plan. Any shares of Stock tendered or withheld to satisfy the grant or exercise price or tax withholding obligation pursuant to any Award shall be treated as issued under this Plan and shall be deducted from the aggregate number of shares which may be issued under Section 2(a). Shares of Stock repurchased on the open market with the proceeds of an exercise price shall not again be available for the grant of an Award pursuant to the Plan. Notwithstanding that a Stock Appreciation Right may be settled by the delivery of a net number of shares of Stock, the full number of shares of Stock underlying such Stock Appreciation Right shall not again be available for the grant of an Award pursuant to the Plan. In addition, no shares of Stock may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as such under Section 422 of the Code.
(c) Calculation of Share Reserve Under the Fungible Ratio. For purposes of determining the number of shares of Stock issuable or transferred pursuant to Section 2(a), each share of Stock which is issued or transferred pursuant to a Full Value Award (i) prior to May 20, 2015, shall be treated as if two shares of Stock had been so issued or transferred, and (ii) on and after May 20, 2015, shall be treated as if 1.17 shares of Stock had been so issued or transferred. To the extent there is issued a share of Stock pursuant to a Full Value Award that counted as more than one share against the number of shares available for issuance under this Section and such share of Stock again becomes available for issuance under the Plan pursuant to this Section, then the number of shares of Stock available for issuance under the Plan shall increase by (A) two shares of Stock for shares returning prior to May 20, 2015, and (B) 1.17 shares of Stock for shares returning on and after May 20, 2015. To the extent permitted by Applicable Law or any exchange rule, shares of Stock issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted against shares of Stock available for grant pursuant to this Plan. The settlement of any Award in cash shall not be counted against the shares available for issuance under the Plan.
(d) Incentive Stock Option Limit. Subject to the provisions of Section 12 relating to capitalization adjustments, the aggregate maximum number of shares of Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 11,637,190 shares of Stock.
(e) Section 162(m) Limitations. Subject to the provisions of Section 12 relating to capitalization adjustments: (i) a maximum of 500,000 shares of Stock subject to Options and SARs (such shares of Stock subject to adjustment to reflect any stock split on or before the effective date of the Plan) whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Award is granted may be granted to any one Participant during any one calendar year, and (ii) a maximum of 500,000 shares of Stock subject to Awards of Performance Units or Awards of Performance Shares may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals). If an Award is subject to vesting or exercise contingent on the attainment during the Performance Period of Performance Goals, then such Award will count only against the limit applicable to Awards of Performance Units and Performance Shares. If a Performance Unit could (but is not required to) be paid out in cash, it will count only against the limit applicable to Awards of Performance Shares and Performance Units.
APPENDIX A
|
43
APPENDIX A CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10, 2017 APPROVED BY STOCKHOLDERS: MAY 18, 2017 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 7, 2019 APPROVED BY STOCKHOLDERS: ______, 2019 1. PURPOSES OF THE PLAN AND PERMITTED AWARDS. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares. 2. SHARES SUBJECT TO THE PLAN. (a) Shares Subject to the Plan. Subject to adjustments as specified in Section 12 of the Plan, the maximum aggregate number of Shares that may be issued under the Plan is 15,737,190 Shares. The Shares may be authorized, but unissued, or reacquired Stock. (b) Treatment of Lapsed Awards. To the extent that an Award terminates, expires, or lapses for any reason, any shares of Stock subject to the Award shall again be available for the grant of an Award pursuant to the Plan. Any shares of Stock tendered or withheld to satisfy the grant or exercise price or tax withholding obligation pursuant to any Award shall be treated as issued under this Plan and shall be deducted from the aggregate number of shares which may be issued under Section 2(a). Shares of Stock repurchased on the open market with the proceeds of an exercise price shall not again be available for the grant of an Award pursuant to the Plan. Notwithstanding that a Stock Appreciation Right may be settled by the delivery of a net number of shares of Stock, the full number of shares of Stock underlying such Stock Appreciation Right shall not again be available for the grant of an Award pursuant to the Plan. In addition, no shares of Stock may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as such under Section 422 of the Code. (c) Calculation of Share Reserve Under the Fungible Ratio. For purposes of determining the number of shares of Stock issuable or transferred pursuant to Section 2(a), each share of Stock which is issued or transferred pursuant to a Full Value Award (i) prior to May 20, 2015, shall be treated as if two shares of Stock had been so issued or transferred, and (ii) on and after May 20, 2015, shall be treated as if 1.17 shares of Stock had been so issued or transferred. To the extent there is issued a share of Stock pursuant to a Full Value Award that counted as more than one share against the number of shares available for issuance under this Section and such share of Stock again becomes available for issuance under the Plan pursuant to this Section, then the number of shares of Stock available for issuance under the Plan shall increase by (A) two shares of Stock for shares returning prior to May 20, 2015, and (B) 1.17 shares of Stock for shares returning on and after May 20, 2015. To the extent permitted by Applicable Law or any exchange rule, shares of Stock issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted against shares of Stock available for grant pursuant to this Plan. The settlement of any Award in cash shall not be counted against the shares available for issuance under the Plan. (d) Incentive Stock Option Limit. Subject to the provisions of Section 12 relating to capitalization adjustments, the aggregate maximum number of shares of Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 15,737,190 shares of Stock. A-1
(e) Share Reserve. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan. 3. ADMINISTRATION OF THE PLAN. (a) Procedure. Unless and until the Board delegates administration to a Committee as set forth below, the Plan shall be administered by the Board. The Board may delegate administration of the Plan to a Committee or Committees of one or more members of the Board. If administration is delegated to a Committee, the Committee shall have the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise. The Board may designate different Committees to administer the Plan with respect to different groups of Service Providers. (b) Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: | (f) Share Reserve. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.(i)
| 3. ADMINISTRATION OF THE PLAN.
(a) Procedure. Unless and until the Board delegates administration to a Committee as set forth below, the Plan shall be administered by the Board. The Board may delegate administration of the Plan to a Committee or Committees of one or more members of the Board. If administration is delegated to a Committee, the Committee shall have the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise. The Board may designate different Committees to administer the Plan with respect to different groups of Service Providers. To the extent that the Administrator determines it to be desirable to qualify Awards granted hereunder as“performance-based compensation” within the meaning of Section 162(m) of the Code, the Plan will be administered by a Committee of two or more“outside directors” within the meaning of Section 162(m) of the Code.
(b) Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:
(i)to determine the Fair Market Value;
|
| (ii) | to select the Service Providers to whom Awards may be granted hereunder; |
| (iii) | to determine the number of Shares to be covered by each Award granted hereunder and the date of grant; the date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such later date as is determined by the Administrator; |
| (iv) | to approve forms of agreement for use under the Plan; |
| (v) | to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine; |
| (vi) | to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; |
| (vii) | to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating tosub-plans established for the purpose of satisfying applicable foreign laws; |
| (viii) | to modify or amend each Award (subject to Section 19(c) of the Plan);provided, however, that Board may amend the terms of an Award without the affected Participant’s consent if necessary (A) to maintain the qualified status of the Award as an Incentive Stock Option, (B) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code, or (C) to comply with other Applicable Law; |
| (ix) | to determine the terms and conditions of any, and with the approval of the Company’s stockholders, to institute an Exchange Program; |
| (x) | to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator; |
| (xi) | to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award; and |
| (xii) | to make all other determinations deemed necessary or advisable for administering the Plan. (c) Prohibition Against Repricing. Subject to adjustments made pursuant to Section 14, in no event shall the Administrator have the right to amend the terms of any Award to reduce the exercise price of such outstanding Award or cancel an outstanding Award in exchange for cash or other Awards with an exercise price that is less than the exercise price of the original Award without stockholder approval.
(d) Effect of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards.
4. ELIGIBILITY.
Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares may be granted to Service Providers. Incentive Stock Options may be granted only to Employees.
APPENDIX A
|
(c) Prohibition Against Repricing. Subject to adjustments made pursuant to Section 14, in no event shall the Administrator have the right to amend the terms of any Award to reduce the exercise price of such outstanding Award or cancel an outstanding Award in exchange for cash or other Awards with an exercise price that is less than the exercise price of the original Award without stockholder approval. (d) Effect of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards. 4. ELIGIBILITY. Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares may be granted to Service Providers. Incentive Stock Options may be granted only to Employees. A-2
5. TERMS RELATING TO STOCK OPTIONS AND STOCK APPRECIATION RIGHTS. Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: (a) Term of Option. The term of each Option or SAR will be stated in the Award Agreement and will not exceed ten years from the date of grant, except that in the case of an Incentive Stock Option granted to a Participant who is a Ten Percent Stockholder, the term of the Incentive Stock Option may not be more than five years from the date of grant. (b) Exercise Price. The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Stock on the date the Award is granted, except that for Options or SARs granted to a Ten Percent Stockholder, the exercise or strike price of each Option or SAR will not be less than 110% of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Stock equivalents. (c) Waiting Period and Exercise Dates. At the time an Option or SAR is granted, the Administrator will fix the period within which the Option or SAR may be exercised and will determine the vesting requirements and any other conditions that must be satisfied before the Option or SAR may be exercised. (d) Exercise of an Option. The Administrator will determine the acceptable method (which may be electronic) and form of consideration for exercising an Option, including the method of payment. Such consideration may include: (i) cash; (ii) check; (iii) promissory note, to the extent permitted by Applicable Laws; (iv) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Option will be exercised and provided that accepting such Shares, in the sole discretion of the Administrator, shall not result in any adverse accounting consequences to the Company; (iv) consideration received by the Company under a cashless exercise program implemented by the Company in connection with the Plan; (vi) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (vii) any combination of the foregoing methods of payment. In the case of an Incentive Stock Option, the Administrator will specify in the Award Agreement the acceptable forms of consideration. (e) Exercise and Payment of a SAR. The Administrator will determine the acceptable method (which may be electronic) to exercise any outstanding SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (i) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Stock equal to the number of Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (ii) the strike price. The appreciation distribution may be paid in Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR. (f) Termination of Relationship as a Service Provider. Except as otherwise provided in the applicable Award Agreement, if a Participant ceases to be a Service Provider, other than for Cause or upon the Participant’s death or Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested portion of his or her Option or SAR until the earlier of three months following the Participant’s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the Option or SAR will terminate, and the Shares covered by such Option or SAR will revert to the Plan. In the case of a Participant terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination as a Service Provider, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination for Cause. A-3
(g) Disability of Participant. Except as otherwise provided in the applicable Award Agreement, if a Participant ceases to be a Service Provider as a result of the Participant’s Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested portion of his or her Option or SAR until the earlier of 12 months following the Participant’s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the Option or SAR will terminate, and the Shares covered by such Option or SAR will revert to the Plan. (h) Death of Participant. Except as otherwise provided in the applicable Award Agreement, if a Participant dies while a Service Provider, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant’s properly designated beneficiary may exercise the Option or SAR until the earlier of 12 months following Participant’s death, or until expiration of the term of such Option or SAR. If no such beneficiary has been designated by the Participant, then such Option or SAR may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option or SAR is transferred pursuant to the Participant’s will or in accordance with the laws of descent and distribution. If the Option or SAR is not so exercised within the time specified herein, the Award will terminate, and the Shares covered by such Option or SAR will revert to the Plan. (i) Rights of Holder of Option. Unless otherwise stated in the applicable Award Agreement, an individual holding or exercising an Option or SAR shall have none of the rights of a stockholder (for example, the right to receive cash or dividend payments or distributions attributable to the subject Shares or to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him. In no case shall an individual holding an Option receive cash or dividend payments or distributions or dividend equivalents attributable to unvested Shares underlying an Option. Except as provided in Section 12(a) hereof, no adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date of such issuance. 6. RESTRICTED STOCK. (a) Grant of Restricted Stock. The Administrator may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. (b) Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator will determine. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Company as escrow agent until the restrictions on such Shares have lapsed. The Administrator may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate. (c) Transferability. Except as provided in this Section 6, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. (d) Removal of Restrictions. Except as otherwise provided in this Section 6, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed. (e) Voting Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. (f) Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise provided in the Award Agreement. Any such dividends will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. For clarity, Service Providers holding Shares of Restricted Stock shall have the right to vote such Shares and the right to receive any dividends declared or paid with respect to such Shares provided that any such dividends shall be subject to the same vesting restrictions as the underlying Shares subject to the Restricted Stock during the Period of Restriction. Such dividends so accrued with respect to the Shares subject to any Award of Restricted Stock, whether subject to time-based and/or performance-based vesting criteria, shall become payable no earlier than the date the applicable vesting criteria have been satisfied and the Period of Restriction with respect to such Shares has lapsed. A-4
(g) Return of Restricted Stock to Company. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. 7. RESTRICTED STOCK UNITS. (a) Grant of Restricted Stock Units; Vesting and Other Terms. Restricted Stock Units may be granted to Service Providers at any time with the number of Units to be determined by the Administrator. The Administrator will set service-based or other vesting provisions in its discretion which, depending on the extent to which they are met, will determine the number of Shares to be issued to the Service Providers. Each Award of Restricted Stock Units will be evidenced by an Award Agreement that will specify the vesting schedule, and such other terms and conditions as the Administrator, in its sole discretion, will determine. (b) Earning of Restricted Stock Units; Form and Timing of Payment. Upon vesting of Restricted Stock Units, the holder thereof will be issued that the number of shares of Stock. Issuance of Shares upon the vesting of Restricted Stock Units will be made as soon as practicable after vesting, but in no event later than the time required to avoid adverse tax consequences under Section 409A of the Code. (c) Cancellation of Restricted Stock Units. If a holder of Restricted Stock Units terminates service prior to the vesting of all Units or as otherwise provided in an Award Agreement, all unvested Restricted Stock Units will be forfeited and will again be available for grant under the Plan. (d) Dividend Equivalents. Dividend equivalents may be credited in respect of Shares covered by an Award Agreement covering a Restricted Stock Unit, as determined by the Board and contained in such Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit credited by reason of such dividend equivalents will be subject to all of the same terms and conditions (including forfeiture restrictions) of the underlying Restricted Stock Unit to which they relate, and such dividend equivalent shall not be paid unless and until the time that the Shares underlying the Restricted Stock Unit are vested and are distributed to the Service Provider. 8. PERFORMANCE UNITS AND PERFORMANCE SHARES. (a) Grant of Performance Units and Performance Shares. Performance Units and Performance Shares may be granted to Service Providers at any time as determined by the Administrator, in such numbers and subject to such other terms and conditions as determined by the Administrator, in its discretion. (b) Value of Performance Units/Shares. Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant. (c) Performance Objectives and Other Terms. The Administrator will set performance objectives or other vesting provisions in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, or individual goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion. (d) Earning of Performance Units/Shares. After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share. (e) Form and Timing of Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair A-5
Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof. (f) Cancellation of Performance Units/Shares. On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited and will again be available for grant under the Plan. (g) Dividends and Other Distributions. No cash dividends or distributions declared with respect to Shares subject to the Performance Units/Shares shall be paid to any Participant unless and until the Participant vests in such underlying Performance Units/Shares. Upon the vesting of a Performance Units/Shares, any cash dividends or distributions declared but not paid during the vesting period with respect to such Performance Units/Shares shall be paid to the Participant at the same time or times as the Shares underlying the Performance Units/Shares. Any stock dividends declared on Shares subject to a Performance Units/Shares shall be subject to the same restrictions and shall vest at the same time as the Performance Units/Shares from which said dividends were derived. All unvested dividends shall be forfeited by the Participants to the extent their underlying Performance Units/Shares are forfeited. 9. PERFORMANCE GOALS. The granting and/or vesting of Awards of Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units and other incentives under the Plan may be made subject to the attainment of performance goals relating to one or more business criteria and may provide for a targeted level or levels of achievement (“Performance Goals”) including, with respect to the Company or any business unit: (a) cash position, (b) clinical progression, (c) collaboration arrangements, (d) collaboration progression, (e) earnings per share, (f) a financing event, (g) net income, (h) operating cash flow, (i) market share, (j) operating expenses, (k) operating income, (l) product approval, (m) product revenues, (n) profit after tax, (o) projects in development, (p) regulatory filings, (q) return on assets, (r) return on equity, (s) revenue growth, (t) total stockholder return, (u) implementation of, progression in or completion of projects or processes (including, without limitation, progress in research or development programs, progress in regulatory or compliance initiatives, clinical trial initiation, clinical trial enrollment, clinical trial results, new or supplemental indications for existing products, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, product supply and systems development and implementation), (v) completion of a joint venture or other corporate transaction, (w) employee retention, (x) budget management and (y) any other measures of performance selected by the Board. The Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any Participant. Any Performance Goals may be used to measure the performance of the Company as a whole or a business unit of the Company and may be measured relative to a peer group or index or to another Performance Goal. With respect to any Award, Performance Goals may be used alone or in combination. The Performance Goals may differ from Participant to Participant and from Award to Award. The Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any Participant. In all other respects, Performance Goals will be calculated in accordance with the Company’s financial statements, generally accepted accounting principles, or under a methodology established by the Administrator prior to the issuance of an Award. 10. LEAVES OF ABSENCE. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Service Provider will not cease to be an Employee in the case of (a) any leave of absence approved by the Company or (b) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed 90 days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six months and a day following the 1st day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option. 11. TRANSFERABILITY OF AWARDS. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award A-6
transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate; provided, however, that the Administrator may only make an Award transferable to one or more of the following: (a) a “family member” (as defined pursuant to Rule 701 of the Securities Act of 1933, as amended) of the Participant; (b) a trust for the benefit of one or more of the Participant or the persons referred to in clause (a); (c) a partnership, limited liability company or corporation in which the Participant or the persons referred to in clause (a) are the only partners, members or stockholders; or (d) charitable donations. 12. ADJUSTMENTS; DISSOLUTION OR LIQUIDATION; MERGER OR CHANGE IN CONTROL. (a) Adjustments. In order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, in the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator shall appropriately adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, the numerical Share limits as specified throughout the Plan. (b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action. (c) Change in Control. In the event of a Change in Control, each outstanding Award will be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding time-based Options and SARs, including Shares as to which such Awards would not otherwise be vested or exercisable, all time-based restrictions on Restricted Stock shall lapse, and, with respect to Performance Shares, Restricted Stock Units and Performance Units, all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and conditions met. | 5. TERMS RELATING TO STOCK OPTIONS AND STOCK APPRECIATION RIGHTS.(i)
| Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical;provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:
(a) Term of Option. The term of each Option or SAR will be stated in the Award Agreement and will not exceed ten years from the date of grant, except that in the case of an Incentive Stock Option granted to a Participant who is a Ten Percent Stockholder, the term of the Incentive Stock Option may not be more than five years from the date of grant.
(b) Exercise Price. The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Stock on the date the Award is granted, except that for Options or SARs granted to a Ten Percent Stockholder, the exercise or strike price of each Option or SAR will not be less than 110% of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Stock equivalents.
(c) Waiting Period and Exercise Dates. At the time an Option or SAR is granted, the Administrator will fix the period within which the Option or SAR may be exercised and will determine the vesting requirements and any other conditions that must be satisfied before the Option or SAR may be exercised.
(d) Exercise of an Option. The Administrator will determine the acceptable method (which may be electronic) and form of consideration for exercising an Option, including the method of payment. Such consideration may include: (i) cash; (ii) check; (iii) promissory note, to the extent permitted by Applicable Laws; (iv) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Option will be exercised and provided that accepting such Shares, in the sole discretion of the Administrator, shall not result in any adverse accounting consequences to the Company; (iv) consideration received by the Company under a cashless exercise program implemented by the Company in connection with the Plan; (vi) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (vii) any combination of the foregoing methods of payment. In the case of an Incentive Stock Option, the Administrator will specify in the Award Agreement the acceptable forms of consideration.
(e) Exercise and Payment of a SAR. The Administrator will determine the acceptable method (which may be electronic) to exercise any outstanding SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (i) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Stock equal to the number of Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (ii) the strike price. The appreciation distribution may be paid in Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.
(f) Termination of Relationship as a Service Provider. Except as otherwise provided in the applicable Award Agreement, if a Participant ceases to be a Service Provider, other than for Cause or upon the Participant’s death or Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested portion of his or her Option or SAR until the earlier of three months following the Participant’s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the Option or SAR will terminate, and the Shares covered by such Option or SAR will revert to the Plan. In the case of a Participant terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination as a Service Provider, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination for Cause.
(g) Disability of Participant. Except as otherwise provided in the applicable Award Agreement, if a Participant ceases to be a Service Provider as a result of the Participant’s Disability, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant may exercise the vested portion of his or her Option or SAR until the earlier of 12 months following the Participant’s termination, or expiration of the Option or SAR. If the Participant does not exercise his or her Option or SAR within the time specified, the Option or SAR will terminate, and the Shares covered by such Option or SAR will revert to the Plan.
APPENDIX A
(h) Death of Participant. Except as otherwise provided in the applicable Award Agreement, if a Participant dies while a Service Provider, any unvested portion of the Option or SAR shall terminate and will revert to the Plan, and the Participant’s properly designated beneficiary may exercise the Option or SAR until the earlier of 12 months following Participant’s death, or until expiration of the term of such Option or SAR. If no such beneficiary has been designated by the Participant, then such Option or SAR may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option or SAR is transferred pursuant to the Participant’s will or in accordance with the laws of descent and distribution. If the Option or SAR is not so exercised within the time specified herein, the Award will terminate, and the Shares covered by such Option or SAR will revert to the Plan.
(i) Rights of Holder of Option.Unless otherwise stated in the applicable Award Agreement, an individual holding or exercising an Option or SAR shall have none of the rights of a stockholder (for example, the right to receive cash or dividend payments or distributions attributable to the subject Shares or to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him. In no case shall an individual holding an Option receive cash or dividend payments or distributions or dividend equivalents attributable to unvested Shares underlying an Option. Except as provided inSection 12(a)hereof, no adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date of such issuance.
6. RESTRICTED STOCK.
(a) Grant of Restricted Stock. The Administrator may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.
(b) Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator will determine. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Company as escrow agent until the restrictions on such Shares have lapsed. The Administrator may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.
(c) Transferability. Except as provided in this Section 6, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.
(d) Removal of Restrictions. Except as otherwise provided in this Section 6, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.
(e) Voting Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.
(f) Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise provided in the Award Agreement. Any such dividends will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. For clarity, Service Providers holding Shares of Restricted Stock shall have the right to vote such Shares and the right to receive any dividends declared or paid with respect to such Shares provided that any such dividends shall be subject to the same vesting restrictions as the underlying Shares subject to the Restricted Stock during the Period of Restriction. Such dividends so accrued with respect to the Shares subject to any Award of Restricted Stock, whether subject to time-based and/or performance-based vesting criteria, shall become payable no earlier than the date the applicable vesting criteria have been satisfied and the Period of Restriction with respect to such Shares has lapsed.
(g) Return of Restricted Stock to Company. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.
7. RESTRICTED STOCK UNITS.
(a) Grant of Restricted Stock Units; Vesting and Other Terms. Restricted Stock Units may be granted to Service Providers at any time with the number of Units to be determined by the Administrator. The Administrator will set service-based or other vesting provisions in its discretion which, depending on the extent to which they are met, will determine the number of Shares to be issued to the Service Providers. Each Award of Restricted Stock Units will be evidenced by an Award Agreement that will specify the vesting schedule, and such other terms and conditions as the Administrator, in its sole discretion, will determine.
APPENDIX A
(b) Earning of Restricted Stock Units; Form and Timing of Payment. Upon vesting of Restricted Stock Units, the holder thereof will be issued that the number of shares of Stock. Issuance of Shares upon the vesting of Restricted Stock Units will be made as soon as practicable after vesting, but in no event later than the time required to avoid adverse tax consequences under Section 409A of the Code.
(c) Cancellation of Restricted Stock Units. If a holder of Restricted Stock Units terminates service prior to the vesting of all Units or as otherwise provided in an Award Agreement, all unvested Restricted Stock Units will be forfeited and will again be available for grant under the Plan.
(d)Dividend Equivalents.Dividend equivalents may be credited in respect of Shares covered by an Award Agreement covering a Restricted Stock Unit, as determined by the Board and contained in such Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit credited by reason of such dividend equivalents will be subject to all of the same terms and conditions (including forfeiture restrictions) of the underlying Restricted Stock Unit to which they relate, and such dividend equivalent shall not be paid unless and until the time that the Shares underlying the Restricted Stock Unit are vested and are distributed to the Service Provider.
8. PERFORMANCE UNITS AND PERFORMANCE SHARES.
(a) Grant of Performance Units and Performance Shares. Performance Units and Performance Shares may be granted to Service Providers at any time as determined by the Administrator, in such numbers and subject to such other terms and conditions as determined by the Administrator, in its discretion. For Performance Units or Performance Shares intended to qualify as“performance-based compensation” within the meaning of Section 162(m) of the Code, (i) no Participant will receive Performance Units/Shares having an initial value greater than $4,000,000, and (ii) no Participant will receive more than 500,000 Performance Units/Shares. Notwithstanding the foregoing limitation, for Performance Units/Shares intended to qualify as “performance-based compensation” within the meaning of Section 162(m) of the Code, in connection with his or her initial service, a Service Provider may be granted up to an additional 500,000 Performance Units/Shares.
(b) Section 162(m) Performance Restrictions. For purposes of qualifying grants of Performance Units/Shares as “performance-based compensation” under Section 162(m) of the Code, the Administrator, in its discretion, may set restrictions based upon the achievement of Performance Goals. The Performance Goals will be set by the Administrator on or before the Determination Date. In granting Performance Units/Shares which are intended to qualify under Section 162(m) of the Code, the Administrator will follow any procedures determined by it from time to time to be necessary or appropriate to ensure qualification of the Award under Section 162(m) of the Code (e.g., in determining the Performance Goals).
(c) Value of Performance Units/Shares. Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant.
(d) Performance Objectives and Other Terms. The Administrator will set performance objectives or other vesting provisions in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, or individual goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.
(e) Earning of Performance Units/Shares. After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share.
(f) Form and Timing of Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof.
(g) Cancellation of Performance Units/Shares. On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited and will again be available for grant under the Plan.
APPENDIX A
(h) Dividends and Other Distributions.No cash dividends or distributions declared with respect to Shares subject to the Performance Units/Shares shall be paid to any Participant unless and until the Participant vests in such underlying Performance Units/Shares. Upon the vesting of a Performance Units/Shares, any cash dividends or distributions declared but not paid during the vesting period with respect to such Performance Units/Shares shall be paid to the Participant at the same time or times as the Shares underlying the Performance Units/Shares. Any stock dividends declared on Shares subject to a Performance Units/Shares shall be subject to the same restrictions and shall vest at the same time as the Performance Units/Shares from which said dividends were derived. All unvested dividends shall be forfeited by the Participants to the extent their underlying Performance Units/Shares are forfeited.
9. PERFORMANCE GOALS.
The granting and/or vesting of Awards of Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units and other incentives under the Plan may be made subject to the attainment of performance goals relating to one or more business criteria within the meaning of Section 162(m) of the Code and may provide for a targeted level or levels of achievement (“Performance Goals”) including, with respect to the Company or any business unit: (a) cash position, (b) clinical progression, (c) collaboration arrangements, (d) collaboration progression, (e) earnings per share, (f) a financing event, (g) net income, (h) operating cash flow, (i) market share, (j) operating expenses, (k) operating income, (l) product approval, (m) product revenues, (n) profit after tax, (o) projects in development, (p) regulatory filings, (q) return on assets, (r) return on equity, (s) revenue growth, and (t) total stockholder return, (u) implementation of, progression in or completion of projects or processes (including, without limitation, progress in research or development programs, progress in regulatory or compliance initiatives, clinical trial initiation, clinical trial enrollment, clinical trial results, new or supplemental indications for existing products, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, product supply and systems development and implementation), (v) completion of a joint venture or other corporate transaction, (w) employee retention, (x) budget management and (y) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Board. Prior to the Determination Date, the Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any Participant. Any Performance Goals may be used to measure the performance of the Company as a whole or a business unit of the Company and may be measured relative to a peer group or index or to another Performance Goal. With respect to any Award, Performance Goals may be used alone or in combination. The Performance Goals may differ from Participant to Participant and from Award to Award. Prior to the Determination Date, the Administrator will determine whether any significant element(s) will be included in or excluded from the calculation of any Performance Goal with respect to any Participant. In all other respects, Performance Goals will be calculated in accordance with the Company’s financial statements, generally accepted accounting principles, or under a methodology established by the Administrator prior to the issuance of an Award. In determining the amounts earned by a Participant pursuant to an Award intended to qualified as “performance-based compensation” under Section 162(m) of the Code, the Administrator will have the right to reduce or eliminate (but not to increase) the amount payable at a given level of performance to take into account additional factors that the Administrator may deem relevant to the assessment of individual or corporate performance for the Performance Period. A Participant will be eligible to receive payment pursuant to an Award intended to qualify as “performance-based compensation” under Section 162(m) of the Code for a Performance Period only if the Performance Goals for such period are achieved.
10. LEAVES OF ABSENCE.
Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Service Provider will not cease to be an Employee in the case of (a) any leave of absence approved by the Company or (b) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed 90 days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six months and a day following the 1st day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.
11. TRANSFERABILITY OF AWARDS.
Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate; provided, however, that the
APPENDIX A
Administrator may only make an Award transferable to one or more of the following: (a) a “family member” (as defined pursuant to Rule 701 of the Securities Act of 1933, as amended) of the Participant; (b) a trust for the benefit of one or more of the Participant or the persons referred to in clause (a); (c) a partnership, limited liability company or corporation in which the Participant or the persons referred to in clause (a) are the only partners, members or stockholders; or (d) charitable donations.
12. ADJUSTMENTS; DISSOLUTION OR LIQUIDATION; MERGER OR CHANGE IN CONTROL.
(a) Adjustments. In order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, in the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation,split-up,spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator shall appropriately adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, the numerical Share limits as specified throughout the Plan.
(b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.
(c) Change in Control. In the event of a Change in Control, each outstanding Award will be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and SARs, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock shall lapse, and, with respect to Performance Shares, Restricted Stock Units and Performance Units, all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and conditions met.
(i)For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the fair market value of the consideration received in the merger or Change in Control by holders of Stock for each Share held on the effective date of the transaction; provided, however, that if such consideration received in the Change in Control is not solely stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received to be solely stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Stock in the Change in Control. The continuation or imposition of vesting terms or other restrictions on Awards in connection with a Change of Control shall not prevent such Awards from being considered assumed for purposes of this Section.
|
| (ii) | Notwithstanding the above, an Award that vests, is earned orpaid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant’s consent;provided, however, a modification to such performance goals only to reflect the successor corporation’s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption. |
| (iii) | If an Option or SAR is not assumed or substituted for in the event of a Change in Control, the Administrator will notify the Participant that the Option or SAR will be fully vested and exercisable for a stated period of time prior to the Change of Control, as determined by the Administrator, and the Option or SAR will terminate upon the expiration of such period. |
| (iv) | With respect to Awards granted to an Outside Director that are assumed or substituted for, if on the date of or following such assumption or substitution the Participant’s status as a Director or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the Participant not at the request of the successor, then the Participant will fully vest in all Awards, and shall have the right to exercise Options and SARs for such periods as provided in the applicable Award Agreement. 13. TAX WITHHOLDING.
(a) Withholding Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant’s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).
APPENDIX A
|
A-7
13. TAX WITHHOLDING. (a) Withholding Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant’s FICA obligation) required to be withheld with respect to such Award (or exercise thereof). (b) Withholding Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the amount required to be withheld, (iii) delivering to the Company already-owned Shares having a Fair Market Value equal to the amount required to be withheld, or (iv) selling a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld. 14. CLAWBACK AND RECOVERY OF AWARDS. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board has adopted a clawback policy that allows the Company to seek repayment of incentive compensation that was erroneously paid. The policy provides that if the Board, or Compensation Committee as applicable, determines that there has been a material misstatement of publicly issued financial results from those previously issued to the public due to a knowing violation of rules and regulations of the Securities and Exchange Commission or Company policy, or the willful commission of an act of fraud, dishonesty, gross recklessness or gross negligence, our Board or Compensation Committee will review all incentive compensation made to our named executive officers during the three year period prior to the restatement on the basis of having met or exceeded specific performance targets. If such payments would have been lower had they been calculated based on such restated results, our Board or Compensation Committee will (to the extent permitted by governing law) seek to recoup the payments in excess of the amount that would have been paid based on the restated results. 15. CONDITIONS UPON ISSUANCE OF SHARES. (a) Legal Compliance. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance. (b) Investment Representations. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required. 16. AMENDMENT AND TERMINATION OF THE PLAN. (a) Amendment and Termination. The Administrator may at any time amend, alter, suspend or terminate the Plan. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. Unless earlier terminated or extended, the Plan will continue in effect until February 26, 2029, at which time it shall terminate without further action on the part of the Board or the Company. (b) Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, without the consent of the Participant. Termination of the Plan will not affect the Administrator’s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination. A-8
17. MISCELLANEOUS (a) Not An Employment or Service Contract. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant’s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant’s right or the Company’s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws. (b) Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained. (c) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). (d) Compliance with Section 409A of the Code. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. (e) Choice of Law. The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules. 18. DEFINITIONS. As used herein, the following definitions will apply: (a) “Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with Section 3 of the Plan. (b) “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition. (c) “Applicable Law” means the requirements relating to the administration of equity-based awards under U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan. (d) “Award” means, individually or collectively, a grant under the Plan of Options, SARs, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares. (e) “Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. (f) “Board” means the Board of Directors of the Company. A-9
(g) “Cause” means, in the absence of any written agreement between the Participant and the Company defining such term, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant under the Plan will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. (h) “Change in Control” means the occurrence of any of the following events: | (b) Withholding Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the amount required to be withheld, (iii) delivering to the Company already-owned Shares having a Fair Market Value equal to the amount required to be withheld, or (iv) selling a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.
| 14. CLAWBACK AND RECOVERY OF AWARDS.
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board has adopted a clawback policy that allows the Company to seek repayment of incentive compensation that was erroneously paid. The policy provides that if the Board, or Compensation Committee as applicable, determines that there has been a material misstatement of publicly issued financial results from those previously issued to the public due to a knowing violation of rules and regulations of the Securities and Exchange Commission or Company policy, or the willful commission of an act of fraud, dishonesty, gross recklessness or gross negligence, our Board or Compensation Committee will review all incentive compensation made to our named executive officers during the three year period prior to the restatement on the basis of having met or exceeded specific performance targets. If such payments would have been lower had they been calculated based on such restated results, our Board or Compensation Committee will (to the extent permitted by governing law) seek to recoup the payments in excess of the amount that would have been paid based on the restated results.
15. CONDITIONS UPON ISSUANCE OF SHARES.
(a) Legal Compliance. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.
(b) Investment Representations. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.
16. AMENDMENT AND TERMINATION OF THE PLAN.
(a) Amendment and Termination. The Administrator may at any time amend, alter, suspend or terminate the Plan. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. Unless earlier terminated or extended, the Plan will continue in effect until May 20, 2025, at which time it shall terminate without further action on the part of the Board or the Company.
(b) Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, without the consent of the Participant. Termination of the Plan will not affect the Administrator’s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.
17. MISCELLANEOUS
(a) Not An Employment or Service Contract. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant’s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant’s right or the Company’s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.
APPENDIX A
(b) Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained.
(c) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).
(d) Compliance with Section 409A of the Code. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.
(e) Choice of Law. The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.
18. DEFINITIONS.
As used herein, the following definitions will apply:
(a)“Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with Section 3 of the Plan.
(b)“Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.
(c)“Applicable Law” means the requirements relating to the administration of equity-based awards under U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.
(d)“Award” means, individually or collectively, a grant under the Plan of Options, SARs, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares.
(e)“Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.
(f)“Board” means the Board of Directors of the Company.
(g)“Cause” means, in the absence of any written agreement between the Participant and the Company defining such term, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant under the Plan will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.
APPENDIX A
(h)“Change in Control” means the occurrence of any of the following events:
(i)Any“person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the“beneficial owner” (as defined in Rule13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or
|
| (ii) | The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets; |
| (iii) | A change in the composition of the Board occurring within atwo-year period, as a result of which less than a majority of the directors are Incumbent Directors.“Incumbent Directors” means directors who either (A) are Directors as of the effective date of the Plan, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or |
| (iv) | The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. |
(i) “Code” means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code will be a reference to any successor or amended section of the Code. (j) “Committee” means a committee of Directors appointed by the Board in accordance with Section 3 of the Plan. (k) “Company” means Cytokinetics, Incorporated, a Delaware corporation, or any successor thereto. (l) “Consultant” means any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render services to such entity. (m) “Director” means a member of the Board. (n) “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code, provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with non-discriminatory standards. (o) “Employee” means any person employed by the Company or any Parent or Subsidiary of the Company. (p) “Exchange Act” means the Securities Exchange Act of 1934, as amended. (q) “Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion, subject to the provisions of Section 4(c). A-10
(r) “Fair Market Value” means, as of any date, the value of Stock determined as follows:
| (i)“Code” means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code will be a reference to any successor or amended section of the Code. | (j)“Committee” means a committee of Directors appointed by the Board in accordance with Section 3 of the Plan.
(k)“Company” means Cytokinetics, Incorporated, a Delaware corporation, or any successor thereto.
(l)“Consultant” means any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render services to such entity.
(m)“Determination Date” means the latest possible date that will not jeopardize the qualification of an Award granted under the Plan as “performance-based compensation” under Section 162(m) of the Code.
(n)“Director” means a member of the Board.
(o)“Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code, provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance withnon-discriminatory standards.
(p)“Employee” means any person employed by the Company or any Parent or Subsidiary of the Company.
(q)“Exchange Act” means the Securities Exchange Act of 1934, as amended.
(r)“Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion, subject to the provisions of Section 4(c).
(s)“Fair Market Value” means, as of any date, the value of Stock determined as follows:
(i)If the Stock is listed on any established stock exchange or a national market system, including without limitation the NASDAQNasdaq Global Market, the NASDAQNasdaq Global Select Market or the NASDAQNasdaq Capital Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;
|
| (ii) | If the Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share of Stock will be the mean between the high bid and low asked prices for the Stock on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or |
| (iii) | In the absence of an established market for the Stock, the Fair Market Value will be determined in good faith by the Administrator. (t)“Fiscal Year” means the fiscal year of the Company.
APPENDIX
|
(s) “Fiscal Year” means the fiscal year of the Company. (t) “Full Value Award” means any Award other than an Option, SAR or other Award for which the Participant pays the intrinsic value (whether directly or by forgoing a right to receive a payment from the Company). (u) “Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations thereunder. (v) “Nonstatutory Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option. (w) “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules thereunder. (x) “Option” means a stock option granted pursuant to the Plan. (y) “Outside Director” means a Director who is not an Employee. (z) “Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Section 424(e) of the Code. (aa) “Participant” means the holder of an outstanding Award. (bb) “Performance Period” means any Fiscal Year or such other period as determined by the Administrator in its sole discretion. (cc) “Performance Share” or “Performance Unit” means an Award granted to a Participant pursuant to Section 8. (dd) “Period of Restriction” means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator. (ee) “Plan” means this Amended and Restated 2004 Equity Incentive Plan. (ff) “Restricted Stock” means shares of Stock issued pursuant to a Restricted Stock Award under Section 6 of the Plan, or issued pursuant to the early exercise of an Option. (gg) “Restricted Stock Unit” shall mean a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 7. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. (hh) “Rule 16b-3” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan. (ii) “Section 16(b)” means Section 16(b) of the Exchange Act. (jj) “Service Provider” means an Employee, Director or Consultant. (kk) “Share” means a share of the Stock, as adjusted in accordance with Section 12 of the Plan. A-11
(ll) “Stock” means the Common Stock of the Company. (mm) “Stock Appreciation Right” or “SAR” means an Award, granted alone or in connection with an Option, that pursuant to Section 5 is designated as a SAR. (nn) “Subsidiary” means a “subsidiary corporation”, whether now or hereafter existing, as defined in Section 424(f) of the Code. (oo) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. A-12
MMMMMMMMMMMM MMMMMMMMMMMMMMM C123456789 000004 ENDORSEMENT_LINE______________ SACKPACK_____________ MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6MMMMMMMMM Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters – here’s how to vote! You may vote online or by phone instead of mailing this card. Votes submitted electronically must be received by 1:00am, Pacific Time, on May 15, 2019. Online Go to www.envisionreports.com/CYTK or scan the QR code — login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/CYTK 2019 Annual Meeting Proxy Card 1234 5678 9012 345 • IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. • Proposals — The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 – 4. A 1. Election of Directors: +For Withhold For Withhold For Withhold 01 - Santo J. Costa 02 - John Henderson, M.B., Ch.B. 03 - B. Lynne Parshall For Against Abstain For Against Abstain 2. Approval of an amendment to the Company's Amended and 3. Ratification of the selection by the Audit Committee of the Restated 2004 Equity Incentive Plan to increase the number of Board of Directors of Ernst & Young LLP as our independent authorized shares reserved for issuance under the 2004 EIP by registered public accounting firm for the fiscal year ending 4,100,000 shares December 31, 2019 For Against Abstain 4. Approval, on an advisory basis, of the compensation of the Named Executive Officers, as disclosed in our Proxy Statement for the 2019 Annual Meeting of Stockholders Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. B Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE C 1234567890 J N T 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 1UPX 405709 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MMMMMMM + 02ZW4F
2019 Annual Meeting Admission Ticket 2019 Annual Meeting of Cytokinetics, Incorporated Stockholders May 15, 2019 10:30 a.m. PT Embassy Suites Hotel 250 Gateway Boulevard, South San Francisco, CA 94080 Upon arrival, please present this admission ticket and photo identification at the registration desk. Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Stockholders. The material is available at: www.envisionreports.com/CYTK Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/CYTK • IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. • Proxy — CYTOKINETICS INCORPORATED + Notice of 2019 Annual Meeting of Stockholders Proxy Solicited by Board of Directors for Annual Meeting — May 15, 2019 Robert Blum and Mark Schlossberg, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of Cytokinetics, Incorporated to be held on May 15, 2019 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR the election of the Board of Directors and FOR items 2-4. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) Non-Voting Items C Change of Address — Please print new address below. Comments — Please print your comments below. +
(u)“Full Value Award” means any Award other than an Option, SAR or other Award for which the Participant pays the intrinsic value (whether directly or by forgoing a right to receive a payment from the Company).
(v)“Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations thereunder.
(w)“Nonstatutory Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.
(x)“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules thereunder.
(y)“Option” means a stock option granted pursuant to the Plan.
(z)“Outside Director” means a Director who is not an Employee.
(aa)“Parent” means a“parent corporation,” whether now or hereafter existing, as defined in Section 424(e) of the Code.
(bb)“Participant” means the holder of an outstanding Award.
(cc)“Performance Period” means any Fiscal Year or such other period as determined by the Administrator in its sole discretion.
(dd)“Performance Share” or“Performance Unit” means an Award granted to a Participant pursuant to Section 8.
(ee)“Period of Restriction” means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.
(ff)“Plan” means this Amended and Restated 2004 Equity Incentive Plan.
(gg)“Restricted Stock” means shares of Stock issued pursuant to a Restricted Stock Award under Section 6 of the Plan, or issued pursuant to the early exercise of an Option.
(hh)“Restricted Stock Unit” shall mean a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 7. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.
(ii)“Rule16b-3” means Rule16b-3 of the Exchange Act or any successor to Rule16b-3, as in effect when discretion is being exercised with respect to the Plan.
(jj)“Section 16(b)” means Section 16(b) of the Exchange Act.
(kk)“Service Provider” means an Employee, Director or Consultant.
(ll)“Share” means a share of the Stock, as adjusted in accordance with Section 12 of the Plan.
(mm)“Stock” means the Common Stock of the Company.
(nn)“Stock Appreciation Right” or“SAR” means an Award, granted alone or in connection with an Option, that pursuant to Section 5 is designated as a SAR.
(oo)“Subsidiary” means a“subsidiary corporation”, whether now or hereafter existing, as defined in Section 424(f) of the Code.
(pp)“Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
C123456789 IMPORTANT ANNUAL MEETING INFORMATION 000004 000000000.000000 ext 000000000.000000 ext ENDORSEMENT_LINE SACKPACK 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext MR A SAMPLE Electronic Voting Instructions DESIGNATION (IF ANY) Available 24 hours a day, 7 days a week! ADD 1 ADD 2 Instead of mailing your proxy, you may choose one of the voting ADD 3 methods outlined below to vote your proxy. ADD 4 VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. ADD 5 Proxies submitted by the Internet or telephone must be received by ADD 6 11:59 p.m., Eastern Time, on May 17, 2017. Vote by Internet • Go to www.investorvote.com/CYTK • Or scan the QR code with your smartphone • Follow the steps outlined on the secure website Vote by telephone • Call toll free1-800-652-VOTE (8683) within the USA, US territories & Canada on a touch tone telephone • Follow the instructions provided by the recorded message Using a black ink pen, mark your votes with an X as shown in X this example. Please do not write outside the designated areas. Annual Meeting Proxy Card 1234 5678 9012 345 IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. A Proposals The Board of Directors recommends a vote “FOR ALL” for Proposal 1, and “FOR” Proposals 2, 3 and 4. 1. Election of Directors: 01—L. Patrick Gage 02—Edward M. Kaye 03—Wendell Wierenga + Mark here to vote Mark here to WITHHOLD For All EXCEPT—To withhold authority to vote for any FOR all nominees vote from all nominees nominee(s), write the name(s) of such nominee(s) below. For Against Abstain For Against Abstain 2. Ratification of selection of PricewaterhouseCoopers LLP 3. Approval of an amendment to the Amended and Restated 2004 as the independent registered public accounting firm of Equity Incentive Plan to increase the number of authorized Cytokinetics, Incorporated for the fiscal year ending shares reserved for issuance thereunder by 3,900,000 shares. December 31, 2017. 4. Approval, on an advisory basis, of the compensation of the named executive officers. The Board of Directors recommends a vote for “EVERY THREE YEARS” for Proposal 5. Every 3 Every 2 Every Abstain Years Years Year 5. Determination, on an advisory basis, of the frequency of the advisory vote on compensation of the named executive officers. B Authorized Signatures — This section must be completed for your vote to be counted. — Date and Sign Below Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. C 1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 1UPX 3 1 7 9 2 1 1 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 02JLPC
Important notice regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 18, 2017. The Proxy Statement, Notice of Annual Meeting, Form of Proxy Card and 2016 Annual Report to Stockholders are available at: cytokinetics.com/proxy IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. + Proxy — Cytokinetics, Incorporated Annual Meeting of Stockholders — May 18, 2017 THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF THE COMPANY The undersigned hereby appoints Robert I. Blum and Caryn G. McDowell, and each of them, with power to act without the other and with power of substitution, as proxies andattorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all the shares of Cytokinetics, Incorporated Common Stock which the undersigned is entitled to vote, and, in their discretion, to vote upon such other business as may properly come before the Annual Meeting of Stockholders of the Company to be held May 18, 2017 or at any adjournment or postponement thereof, with all powers which the undersigned would possess if present at the Annual Meeting of Stockholders. (Continued and to be marked, dated and signed, on the other side) CNon-Voting Items Change of Address — Please print new address below. Comments — Please print your comments below. IF VOTING BY MAIL, YOU MUST COMPLETE SECTIONS A—C ON BOTH SIDES OF THIS CARD. +
|